Protocol 05 Protocol (b) J2G-MC-JZJU
An Open-Label, Randomized Study to Evaluate the Relative Bioavailbility of Selpercatinib in 3 Formulations 
for Pediatric Use
[STUDY_ID_REMOVED]
Approval Date: 22-Nov-2021
CONFIDE NTIAL Protocol number J2G-M C-JZW (b) 
Title Page 
Confidential Information 
The information contained in this document is confidential and is intended for the use of clinical investigators . It is the property of 
Eli Lilly and Company or its subs idiaries and shou ld not be copied by or distributed to persons not involve d in the clinical 
investigation of selpercat inib (L Y3527723 ) unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiar ies. 
Note to Regulatory Author ities: This document may conta in protected persona l data and/or commercially confidential information 
exempt from public disclosure . Eli Lilly and Company requests consultat ion regard ing release /redacti on pr ior to any public release. 
In the United States , this document is subject to Freedo m of Informat ion Act Exempt ion 4 and may not be reproduced or otherwise 
disseminated without the written approval of Eli Lilly and Company or its subsidiar ies. 
Protocol Title: An Open-Label , Randomized Study to Evaluate the Relative Bioavailability of 
Selpercatinib in 3 Formul ations for Pediatric Use 
Protocol Number: J2G-M C-JZm 
Amendment Number: (b) 
Compound: L Y3527723 
Brief Title: A Rela tive Bioavailability Study ofSelper catinib Fornmlation s for Pediatric Use 
Study Phase: 1 
Sponsor Name : Eli Lilly and Company on behalf ofLoxo Oncology, Inc., a who lly owned 
subsidiary of Eli Lilly and Company 
Legal Registered Address: Indianapolis, Indiana 4 6285 USA 
Regulatory Agency Identifier Number( s) 
IND: 133193 
Approval Date: Proto col Electronically Sig ned and Appro ved by Lilly on date provided below. 
Appro val Date: 22-No v-2021 GMT 
1 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Original Protocol 19-July -2021
Amendment (a) 07-Sep -2021
Amendment [b] 
This amendment is considered to be nonsubstant ial.
Overall Rationale for the Amendment:
The protocol is amended to correct the timepo intsfor clinical laboratory  assessments in the 
Schedule of Act ivities.The fo llowing table describes the change made in amendment ( b).
Section # and Name Description of Change Brief Rationale
1.3 Schedule of 
ActivitiesPhysical examinat ion added to 
Day 21.Missing assessments added.
1.3 Schedule of 
ActivitiesPregnancy test removed fro m 
early  discontinuat ion.Not required.
1.3 Schedule of 
ActivitiesAdded ECG assessments to 
Day 21.Missing assessments added.
1.3 Schedule of 
ActivitiesAdded vital signs assessments to 
Day 21.Missing assessments added.
1.3 Schedule of 
ActivitiesMoved time points for collect ion 
of clinical laboratory  tests from  
Day 8 to Day  9 (24 hours 
postdose).
Moved time points for collect ion 
of clinical laboratory  tests from  
Day 15 to Day  16 (24 hours 
postdose).
Added co llection of clinical 
laborato ry tests on Day  21.To correct the schedule of 
activit ies for incorrect and 
missing clinical laboratory  
assessment time points.
5.1 Incl usion CriteriaAmended the age range for 
participant inclusio n.Per site request .
10.2 Appendix 2: 
Clinical Laboratory
TestsAdded total  Cho lesterol, HDL -C, 
and LDL -C as clinical chemistry  
param eters .New param eters now 
requi red as part of clinical 
chemistry  assessment.
10.2 Appendix 2: 
Clinical Laboratory  
TestsAdded footnote ‘e’ to outline 
timing of pregnancy tests .For accuracy .
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
4Table of Contents
1. Protocol Summary ...................................................................................................... 7
1.1. Synopsis ....................................................................................................................... 7
1.2. Schema ......................................................................................................................... 9
1.3. Schedule of Act ivities (SoA) ...................................................................................... 10
2. Introduction .............................................................................................................. 14
2.1. Study  Rati onale .......................................................................................................... 14
2.2. Background ................................................................................................................ 14
2.3. Benefit/Risk Assessment ............................................................................................ 14
3. O bjectives and Endpoints ......................................................................................... 16
4. Study Design ............................................................................................................. 17
4.1. Overall Design ............................................................................................................ 17
4.1.1. Screening .................................................................................................................... 17
4.1.2. Treatment and Assessment Period............................................................................... 17
4.2. Scientific Rationale for Study  Design ......................................................................... 18
4.3. Justification for Dose .................................................................................................. 18
4.4. End of Study  Definit ion.............................................................................................. 18
5. Study Population ...................................................................................................... 19
5.1. Inclusio n Cri teria........................................................................................................ 19
5.2. Exclusio n Cri teria....................................................................................................... 20
5.3. Lifest yle Considerat ions............................................................................................. 22
5.3.1. Meals and Dietary  Restri ctions................................................................................... 23
5.3.2. Caffeine, Alcoho l, and Tobacco .................................................................................. 23
5.3.3. Activity...................................................................................................................... 23
5.4. Screen Failures ........................................................................................................... 23
6. Study Intervention(s) and Concomitant Therapy ................................................... 24
6.1. Study  Intervent ion(s) Administered ............................................................................ 24
6.1.1. Administrati on Details ................................................................................................ 24
6.2. Preparati on, Handling, Storage, and Accountabilit y.................................................... 24
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 25
6.4. Study  Intervent ion Compliance ................................................................................... 25
6.5. Dose Modificat ion...................................................................................................... 25
6.6. Continued Access to Study  Intervent ion After the End of the 
Study .......................................................................................................................... 25
6.7. Treatment of Overdose ............................................................................................... 25
6.8. Concomitant Therapy .................................................................................................26
7. Disco ntinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 27
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 27
7.1.1. Liver Chemistry  Stopping Cri teria.............................................................................. 27
7.1.2. QTc Stopping Criteria .................................................................................................28
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 28
7.3. Lost to Follow -up....................................................................................................... 28
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
58. Study Assessments and Procedures ......................................................................... 30
8.1. Efficacy Assessments .................................................................................................30
8.2. Safety Assessments .................................................................................................... 30
8.2.1. Physical Examinat ions................................................................................................ 30
8.2.2. Vital Signs.................................................................................................................. 30
8.2.3. Electrocardiograms ..................................................................................................... 31
8.2.4. C linical Safety Laboratory  Tests ................................................................................. 31
8.2.5. Pregnancy Testing ...................................................................................................... 31
8.2.6. Safety Moni toring ....................................................................................................... 32
8.3. Adverse Events, Serious Adverse Events, and Product 
Com plaint s................................................................................................................. 34
8.3.1. Timing and Mechanism for Collect ing Events ............................................................ 34
8.3.2. Pregnancy ................................................................................................................... 36
8.3.3. Product Complaint s.................................................................................................... 37
8.4. Pharmacokinet ics........................................................................................................ 37
8.5. Pharmacodynamics ..................................................................................................... 38
8.6. Genet ics..................................................................................................................... 38
8.7. Biomarkers ................................................................................................................. 38
8.8. Immunogenicit y Assessments ..................................................................................... 38
8.9. Heal th Economics ....................................................................................................... 38
8.10. Product Acceptabilit y and Palatabilit y Assessments .................................................... 38
9. Statistical Considerations ......................................................................................... 39
9.1. Statistical Hypotheses .................................................................................................39
9.2. Analyses Sets ............................................................................................................. 39
9.2.1. Study  Parti cipant Disposit ion...................................................................................... 39
9.2.2. Study  Parti cipant Characterist ics................................................................................. 39
9.2.3. Treatment Compliance ................................................................................................ 39
9.3. Statistical Analyses ..................................................................................................... 39
9.3.1. Safety Analyses .......................................................................................................... 39
9.3.2. Pharmacokinet ic Analyses .......................................................................................... 40
9.3.3. Pharmacodynamic Analyses ....................................................................................... 40
9.3.4. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 40
9.4. Interim Analysis ......................................................................................................... 41
9.5. Sample Si ze Determinat ion......................................................................................... 41
10. Supporting Documentation and Operational Considerations ................................ 42
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 42
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 42
10.1.2. Inform ed Consent Process .......................................................................................... 43
10.1.3. Data Protection ........................................................................................................... 43
10.1.4. Disseminat ion of Clinical Study  Data ......................................................................... 43
10.1.5. Data Qualit y Assurance .............................................................................................. 44
10.1.6. Source Documents ...................................................................................................... 45
10.1.7. Study  and Si te Start and Cl osure ................................................................................. 45
10.1.8. Publicat ion Policy ....................................................................................................... 46
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 47
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
610.2.1. Blood Sam pling Summary .......................................................................................... 48
10.3. Appendix 3: Adverse Events and Serious Adverse Events: 
Definit ions and Procedures for Recording, Evaluating, Fo llow-
up, and Reporting ....................................................................................................... 49
10.3.1. Definit ion of AE......................................................................................................... 49
10.3.2. Definit ion of SAE ....................................................................................................... 50
10.3.3. Definit ion of Product Complaint s............................................................................... 51
10.3.4. Recording and Fo llow-Up of AE and/or SAE and Product 
Com plaint s................................................................................................................. 51
10.3.5. Reporting of SAEs ...................................................................................................... 53
10.3.6. Regulatory  Reporting Requirements ........................................................................... 53
10.4. Appendix 4: Contraceptive and Barrier Guidance ....................................................... 55
10.4.1. Definit ions.................................................................................................................. 55
10.4.2. Contraception Guidance .............................................................................................. 55
10.5. Appendix 5: Geneti cs.................................................................................................58
10.6. Appendix 6: Liver Safet y: Suggested Actions and Follow -up 
Assessments ............................................................................................................... 59
10.7. Appendix 7: Abbreviat ions and Definit ions................................................................ 64
10.8. Appendix 8: Protocol Amendment History .................................................................66
11. References ................................................................................................................. 68
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
71. Protocol Summary
1.1. Synopsis
Protocol Title: An Open -Label, Rando mized Study to Evaluate the Relat ive Bioavailabil ity of 
Selpercat inib in 3 Formulat ions for Pedi atric Use
Brief Title: A Relat ive Bioavailabilit yStudy  of Selpercat inibForm ulations f or Pedi atric Use
Rationale :
This is a bioavailabilit y testing the different formulation that has been used in pediatric studies
Objectives ,Endpoint s, and Estimands:
Object ives Endpoints
Primary
To evaluate the relative bioavailabilit y 
of RTU and PFOS suspensio ns
compared to the capsule formulationCmax, AUC(0 -∞), AUC0 -tlast, and 
tmaxof selpercat inib
Secondary
To evaluate the safet y and tol erabili ty 
of a single dose of 20 -mg oral dose of 
selpercat inib RTU and PFOS
suspensions
To assess the palatabilit y of 
selpercat inibRTU and PFOS 
suspensionsSummary  of the number , severit y, and 
typeoftreatm ent-emergent AEs and 
serious adverse events
Responses to palatabilit y 
questionna ire (RTU suspensio n only )
Overall Design :
Study  JZJU will be an open -label, Phase 1 rando mized, 3 -formulation, 3-period, crossover study  
in adult heathy male and female participants. T he ready -to-use (RTU) 20 mg suspensio n and the 
powder for oral suspensio n (PFOS )20 m g/mL suspensi onwill be co mpared to the 20 m g capsule 
formulation
Safety assessments, including AEs, concomitant medicat ions, m edical assessments, clinical 
laboratory  tests, vi tal signs, and ECGs, and blood sampling fo r PK, will be performed.
Screening
All participants will be screened within 28 days prior to enrollment.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
8Treatment and Assessment Period
Parti cipants will be admitted to the CRU on Day  -1. On the morning of Day  1, parti cipants will 
be randomized to 1 of 3 treatment sequences and will receive single doses of 20 -mg selpercat inib 
on each of Days 1, 8, and 15 as either the RTU suspensio n, the P FOS, or the capsule, and will be 
dosed according to the randomization sequence following an overnight fast of at least 10 hours.
The treatment sequences to be used are as fo llows:
Abbreviations: PFOS = powder for oral suspension; RTU = ready to use.
Ther e will be a washout of 7 day s between doses of selpercat inib.
Parti cipants will remain resident at the CRU for the full duration of the treatm ent peri od (i.e., up 
to Day  21).
Number of Participant s:
Up to approximately  42 partici pants will be enrolled to ensure that at least approximately 
36participants complete the study .
Intervention Groups and Duration :
Parti cipants will partici pate in 1 treatm ent.
The study  durati on for all participants i s expected to be up to 59 day s.
Data Monitoring Committee: No
Treatment Sequence A •LI ~~'===~f--=..,.•I •==-, .. 1 
Treatment Sequence B .1 
Treatment Sequence C 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
91.2. Schema
Abbreviations: CRU = clinical research unit; PFOS = powder for oral suspension; RTU = ready to use.
T* * * 
-28 -1 1 8 15 21 
screen ing * 20 mg selper catinib as either the R TU suspension, the PFOS, or the capsule, according to the randomization schedule 
T admis sion to the CRU 
T discharge from the CRU / study discharge 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
101.3. Schedule of Activities (SoA)
Screening Days ED Comments
Procedure -28 to -2 
days prior 
to Day 1-
11 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Informed 
consentX
Inclusion and 
exclusion 
criteriaX
Demography X
Participant 
Admission to 
CRUX
Participant 
Discharge 
from CRUX
Outpatient visit X
Medical 
history 
(includes 
substance 
usage [and 
family history 
of premature 
cardiovascular 
disease])X
Past and 
current 
medical 
conditionsX
Physical 
examinationX X X XFull physical 
examination 
(including 
height and 
weight) to be 
performed at 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
11Screening Days ED Comments
Procedure -28 to -2 
days prior 
to Day 1-
11 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
screening. 
Symptom -
driven 
physical 
examination
s to be 
performed at 
all other 
timepoints.
Serum or urine 
pregnancy test 
(all females )X XSerum 
pregnancy 
test will be 
performed at 
screening. 
Urine 
pregnancy 
test will be 
performed at 
admission to 
the CRU.
HIV, and 
hepatitis B and 
C screenX
Urine or breath 
ethanol test X X
Urine drug 
screenX X
12-lead ECG XP, 
2hP, 
2hP, 
2hX XSingle ECGs 
are required.
Vital signs 
(supine)X XP, 
1, 
2h24
hXP, 
1, 
2h24
hXP, 
1, 
2h24
hX X XTime points 
may be 
added, if 
warranted 
and agreed 
upon 
between 
CONFIDE NTIAL Proto col number J2G-M C-JZW (b) 
Scree ning Days ED Comments 
-28 to -2 
Procedure days prior 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
to Da 1 
Lilly and the 
investigator. 
Asses sment s 
on Days 5 
12, and 19 
shou ld be 
pe1formed in 
themom ing 
at a time 
relati ve to 
predo se on 
Days I, 8 
and 15, 
res ective l 
See 
Appe ndix 2 
Clinical (Sectio n 
labora tory tests X X 24 X 24 X 24 X X 10.2), 
(include liver h h h Clinica l 
chemistrie, s) Laborato1y 
Tests, for 
details. 
Geneti c sample X 
12 
CONFID ENTIAL 
Procedure 
Randomizatio n 
Selperca tinib 
adminis tration 
Taste 
Assessmen t 
Questiollllaire 
Adverse event 
/Serious 
adve rse event 
review 
Concomi tant 
medi cation 
review Screening 
-28 to -2 
X 
X 2 3 4 
X 
X 
X 
X 
X 5 6 7 8 
X 
X Protoc ol number J2G-MC-JZW(b) 
Days 
9 10 11 12 13 14 15 16 17 18 19 20 21 
X 
X ED Comm ents 
X 
X Tobe 
performed 
fortheRTU 
suspension 
andPFOS 
fonn ulations 
only 
immediate ly 
after dosin . 
Abbreviations: CRU = clinical research unit; ECG = electrocardiogra m; ED= early discont inuation; HIV = human immunodeficiency vims; P = predo se; 
PFOS = powder for oral suspension; PK= phaimacokine tic; RTU = ready to use. 
13 
CONFIDENTIAL Protocol number J2G-MC-JZW(b) 
2. Introdu ction 
Selpercatinib (L Y3527723) has been deve loped by Loxo Onco logy, Inc and acquired by Eli Lilly 
and Company (Lilly), and has been approved by the Food and Drng Administration for the 
t1eatment of advanced or metastatic RET-muta nt MTC ; advanced or metastatic RET fusion-
positive thyroid cancer, in adults and children 2'.12 years ; and for the treatment of metastatic RET 
fusion-pos itive non-small cell lung carcinoma (NSC LC) in adults. Full details of the precli nical 
and clinica l safety and tolerab ility data are contained in the invest igator's brochure (IB). 
2.1. Study Rational e 
This is a relative bioavailability study testing the different fo1mu lations that has been used in 
pediatric studies. 
2.2. Ba ckground 
Selpercatin ib (L Y3527723) is a highly potent and specific small-molecule inhibitor of the RET 
kinase , with minima l inhibition of other kinase and nonkinase targets. 
Selpercatin ib doses have been evaluated in healthy paiticipants and patients with advanced or 
metastat ic RET -mutant MTC, advanced or metastat ic RET fusion-positi ve thyroid cance r, other 
RET fusion-posit ive solid tumors, and metastat ic RET fusion-positive NSCLC across Phase 1, 2, 
and 3 clinica l studies. Across these studies, single oral doses of selpercatinib were administered 
over a range of 20 to 720 mg. Mult iple oral doses of 160 mg/day selpercatin ib were administered 
orally twice daily for 10 days in healthy volunteers. Pediactric dose was selected to be 92 mg/m2, 
(maximum 160 mg BID). 
The phaimaco kinetics of selpercatinib is characterized by good oral bioavailabil ity, with a tmax 
of approx in1ately 2 hours (range Oto 8.1 hours). CYP3A4 mediated metabolism constitutes the 
major route of elimination , and the t½ is approximately 32 hours in healt hy voluntee rs. The 
V ss/F and CL/F of selpercatinib increased with increasing body weight (2 7 kg to 177 kg). No 
clinica lly significant differences in the PK of selpercatinib were observed based on age (15 years 
to 90 years) , or sex. As the PK of selpercatinib have been demonst rated to be linear in the dose 
range of 20 to 160 mg in adult cancer patients , results from study JZm can be expected to be 
applicab le across the therape utic dose range. 
More detailed info1mation about the pha1macokinetics (PK) and absorption , distributi on, 
metabolism , and excretion properties of selpercatinib may be found in the IB. 
2.3. Benefit /Risk Assess ment 
There is no anticipated therapeut ic benefit for the healthy pa1ticipants in this study. However , 
participants may benefit from the screening procedures (through detection of unknown health 
issues) even if they receive no therapeut ic benefit from the study. 
14 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
15The dose of selpercat inib to be given in this study is 20mg. The safet y profile o f selpercat inib is 
very well tol erated in healt hy vo lunteers, wi th the low rates of study  drug discont inuat ion due to 
adverse events ( AEs). 
As outlined in the IB, the most commo n toxi cities associ ated wi th selpercat inib in pat ients are 
monitorable and reversible and include dry  mouth, diarrhe a, hypertensi on, fatigue, const ipation, 
AST/ALT elevat ion, headache, nausea, edema peripheral, abdo minal pain, rash, 
electrocardi ogram  (ECG) QT prolonged, cough, vomit ing, dy spnea and increased blood 
creatinine. Events of special interest include hypersens itivity, liver-function test abnorm alities, 
thrombocy topenia, and hypertensio n. None of these events of special interest have been observed 
to date in healt hy part icipants.
More detailed informat ion about the known and expected benefits and risks and reaso nably 
expected AEs of selpercatinib may be found in the IB.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
163. Objectives andEndpoints
Object ives Endpoints
Primary
To evaluate the relative bioavailabilit y 
of RTU and PFOS suspensio ns
compared to the capsule formulationCmax, AUC(0 -∞), AUC0 -tlast, and 
tmaxof selpercat inib
Secondary
To evaluate the safet y and tol erabili ty 
of a single 20 -mg oral dose of 
selpercat inib RTU and PFOS
suspensions
To assess the palatabilit y of 
selpercat inibRTU and PFOS
suspensionsSummary  of the number , severit y,and 
typeoftreatm ent-emergent AEs and 
serious adverse events
Responses to palatabilit y 
questionnaire (RTU suspensio n only )
Abbreviations: AE=adverse event; AUC(0 -∞)= area under the concentration versus time curve from time zero to 
infinity ; AUC0 -tlast=area under the concentration versus time curve from time zero to time t, where t is the last 
time point with a measurable concentration ; Cmax =maximum observed drug concentration ; PFOS= powder for 
oral suspension; RTU = ready to use; t max=time to maximum observed drug concentration.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
174. Study Design
4.1. Overall Design
Study  JZJU will be an open -label, Phase 1 rando mized, 3 -formulation, 3-period, crossover study  
in adult heathy male and female participants. T he ready -to-use (RTU) 20-mg suspensio n and the 
powder for oral suspensio n (PFOS )20 m g/mL formulat ion will be compared to the 20 m g 
capsule form ulation.
The schemat icin Sect ion1.2illustrate sthe study  design . 
Safety assessments, including AEs, concomitant medicat ions, m edical assessments, clinical 
laboratory  tests, vi tal signs, and ECGs, and blood sampling for PK, wil l be perform ed according 
to the SoA (Section 1.3).
4.1.1. Screening
All participants will be screened within 28 days prior to enrollment.
4.1.2. Treatment and Assessment Period
Parti cipants will be admitted to the clinical research unit ( CRU )on Day  -1. On the morning of 
Day 1, parti cipants will be randomized to 1 of 3 treatment sequences and will receive single 
doses of 20 mg selpercat inib on each of Days 1, 8, and 15as either the RTU suspensio n, the 
PFOS , or the capsule , and will be dosed according to the rando mizat ion sequence following an 
overnight fast of at least 10 hours.
The treatment sequences to be used are as fo llows:
Abbreviations: PFOS = powder for oral suspension; RTU = ready to use.
There will be a washout of 7 day s between doses of selpercat inib.
Parti cipants will remain resident at the CRU for the full duration of the treatm ent peri od (i.e., up 
to Day  21)
.
Treatment Sequence A 
Treatment Sequence B 
Treatment Sequence C 
CONFIDENTIAL Protocol number J2G-MC-JZW(b) 
4.2. S cientifi c Rationale for Study Design 
In order to allow each paiticipant to act as his/her own control for safety and PK compai·isons, a 
3-per iod crossover design has been selected. This study will also be open label as the study 
prima1y endpo int PK measures are object ive rathe r than subjective. 
Conducting the study in healthy adult pa1ticipants mitigates the potential confounding effects of 
the disease state and concomitant medications in pa1ticipants with metastatic RET 
:fosion-pos itive NSCLC, advanced or metastatic RET -mutant MTC, or advanced or metastatic 
RET :fosion-positive thyro id cancer. A population of healthy pa1tic ipants is frequent ly used in the 
assessment of the PK of both small and large molec ules. 
The doses, paiticipant popu lation , study duration, and sample collection timing are cons idered 
adequate to achieve the study object ives. 
4.3. Justificati on for Dose 
Dose being used is representative of the typical dose size to be used in pediatric studies. As the 
PK of selpercatinib have been demonstrated to be lineai · in the dose range of m 
adult cancer patients , results from study JZm can be expected to be applicable across the 
therape utic dose range. 
4.4. End of Study De finition 
A pa1ticipant is considered to have completed the study if he/she has completed all required 
periods of the study including the last visit or the last scheduled procedure shown in the SoA. 
The end of the study is defined as the date of the last visit of the last pa1tic ipant in the study. 
18 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
195. Study Population
Eligibilit y of parti cipants for enrollment in the study  will be based on the results of screening 
medical histor y, physical examinat ion, vital signs, clinical laboratory  tests, and ECG.
The inclusio n and exclusio n criteria used to determine eligibilit y shoul d be applied at screening 
only, and not continuously throughout the study . Clinical laboratory  assessments and vital signs 
may be repeated from screening through Day  -1 at the discret ion of the invest igator in order to 
confirm eligibilit y.
Screening may occur up to 28 day s prior to enrollment. Parti cipants who are not enrolled within 
28 day s of screening may  under go an addit ional medi cal assessment and/or clinical 
measurements to confirm their eligibilit y. In such instances, the following screening tests and 
procedures should be repeated: clinical laboratory assessments and vital signs.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criter ia apply:
Age
1.Parti cipant m ust be 18 to 65 y ears of age, inclusive, at the time of signing the informed 
consent form (ICF) .
Type of Participant and Disease Characteristics
2.Parti cipants who are overtly healt hy as determined by  medical evaluat ion including 
medical history , physical examinat ion, and vital signs .
3.Parti cipants who have clinical laboratory test results within the normal reference range 
for the popul ation or invest igative site, or results wit h acceptable deviat ions that are 
judged to be not clinically significant by the investigator.
4.Parti cipants who have venous access sufficient to allow for blood sampling as per the 
protocol .
Weight
5.Have a body  mass index within the range 18.0 to 35.0 kg/m2(inclusive).
Sexand Contraceptive/Barrier Requirements
6.Male or female participants - contraceptive use by  men or wom enshoul d be consistent 
with local regulat ions regarding the methods of contraception for those par ticipat ing in 
clinical studies.
a.Male parti cipants:
Are not requi red to adhere to con tracepti ve requi rements .
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
20b.Female participants:
Female participants of childbearing potential (see Appendix 4 [Secti on10.4])who 
are abst inent (if this is co mplete abst inence, as their preferred and usual lifestyle) 
or in a same -sex relati onship (as part of their preferred and usual lifest yle) must 
agree to either remain abst inent or stay in a same -sex relati onship wi thout sexual 
relationships wit h males.
Periodic abst inence (e.g. ,calendar, ovul ation, symptothermal, post -ovulation 
methods), declaration of abst inence just for the duration of a study , and 
withdrawal , are not acceptable m ethods of contraception.
Female parti cipants of childbearing potential, who are not abstinent as described 
above, must agree to use a highly  effect ive method of contraception (that is, one 
with less than 1% failure rate) such as combinat ion oral  contraceptives, 
implanted/injected contraceptiv es, intrauteri ne devices, or sterile partner until 
30days after the l ast dose of study  medicati on.
Female participants not of childbearing potential are not required to use 
contraception. This includes females who are:
oInfert ile due to surgical sterilization (hysterectomy, bilateral 
oophorectomy , bilateral  salpingectomy , bilateral tubal occlusio n,or 
bilateral tubal  ligation), or congeni tal anom aly (f or example, Müllerian 
agenesis)
oPostmenopausal  as defined in Appendix 4 (Secti on10.4).
Informed Consent
7.Capable of giving signed informed consent as described in Appendix 1 (Secti on10.1),
which includes co mpliance wit h the requirements and restrictions listed in the ICF and in 
this protocol .
5.2. Exclusion Criteria
Parti cipants are excluded fro m the study  if any of the fo llowing cri teria apply:
Medical Conditions
1.Have a posit ive pregnancy test at screening or Day -1, where applicable .
2.Are planning to beco me pregnant during the study or within 1 mo nth of study  
completion.
3.Are women wh o are l actating .
4.Have known allergies to selpercatinib -related com pounds or any components of the 
formulation of selpercat inib, or history  of significant atopy .
5.Have a history  of allergic react ions to medicat ions or food products .
6.Have a clinically  significant abnormalit y of blood pressure and/or pulse rate as
determined by the invest igator .
7.Clinically significant abnormalit ies on ECG as determined by the invest igator or
prolongati on of  the corrected QT interval using or Fridericia’s form ula (QTcF ) >450 
msec at screening .
CONFIDENTIAL  Protocol number J2G- MC-JZJU (b)  
 21 8. Have clinically significant active cardiovascular disease or history of myocardial  
infarction within 6 months prior to the planned start of selpercatinib. 
9. Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal, 
endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of da ta. Appendectomy, 
uncomplicated hernia, splenectomy, and cholecystectomy are considered as acceptable. 
10. Have a creatinine clearance <60 mL/min, as calculated using the Chronic Kidney Disease 
Epidemiology Collaboration ( CKD- EPI) equation  (Levey et al, 2009). 
eGFR = 141 × min(Scr/K, 1)
α × max(Scr/K, 1) -1.209 × 0.993 age 
× 1.018 (if female) 
× 1.159 (if black) 
11. Show a history of central nervous system conditions such as strokes, transient ischemic 
attacks, significant head trauma, seizures, central nervous system infections, migraine, 
brain surgery, or any other neurological conditions that, in the opinion of the investigator,  increase the risk of participating in the study . 
12. Have a history or presence of neuropsychiatric disease (e.g., bipolar disorder, schizophrenia, depression) considered as clinically significant by the investigator . 
13. Regularly use known drugs of abuse or show positive findings on drug screening. 
14. Show evidence of human immunodeficiency virus infection and/or positive human immunodeficiency virus antibodies. 
15. Presence of hepatitis B surface antigen at screening or within 3 months prior to first dose of study intervention. 
16. Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.  NOTE: Parti cipants with positive hepatitis C antibody due to prior resolved disease can 
be enrolled if a confirmatory negative hepatitis C RNA test is obtained. 
17. Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.  NOTE: Test is optional and participants with negative  hepatitis C antibody test are not 
required to also undergo hepatitis C RNA testing. 
18. Have donated blood of more than 500 mL within the previous 3 months of study screening . 
19. Have any medical conditions, medical history, or are taking any medications that  are 
contraindicated in the selpercatinib  label . 
P ri o r/ C o n co m i t a n t  T h e ra p y  
20. Have participated, within the last 30 days of admission, in a clinical study involving an investigational product. If the previous investigational product has a long half- life, 
5 half -lives or 30 days (whichever is longer) should have passed. 
21. Have previously completed or withdrawn from this study or any other study investigating selpercatinib, and have previously received the investigational product. 
C O N FI D E N TI A L  Pr ot oc ol n u m ber J 2 G- M C -J ZJ U ( b )  
 2 2 2 2.  Use of H 2 bl oc kers, pr ot o n- p u m p i n hi bit ors, a n d ot her a ntaci ds  wit hi n 7 d a ys of 
scree ni n g . 
2 3.  Are i nte n di n g t o use o ver-t he-c o u nter or pr escri pti o n me dicati o n, i ncl u di n g dietar y 
s u p ple me nts, wit hi n 1 4 da ys pri or t o d osi n g a n d u ntil st u d y disc h ar ge (a part fr o m 
occasi o nal aceta mi n o p he n ( ≤ 2 g/ 2 4 h o urs), h or m o nal c o ntrace pti o n, or 
h or m o ne- re pl ace m e nt t hera p y) . 
P r i o r / C o n c u r r e n t  C l i n i c a l  S t u d y  E x p e r i e n c e  
2 4.  Are c urre ntl y e nr olle d i n a n y ot h er cli nical st u d y i n v ol vi n g a n i n vesti gati o n al pr o d uct 
or a n y ot her t y pe of me di cal res ear c h j u d ge d n ot t o be scie ntificall y or me dicall y 
c o m pati ble wit h t his st u d y  
O t h e r  E x c l u s i o n s  
2 5.  Ha ve a n a ver a ge w ee kl y alc o h ol i nta ke t hat e x cee ds 2 1 u nits per wee k ( m ales) a n d 1 4 
u nits per wee k (fe mal es ); 1 u nit = 1 2 oz or 3 6 0 m L of b eer; 5 oz or 1 5 0 m L of wi ne; 
1. 5 oz or 4 5 m L of distille d s pirit(s) 
2 6.  Are u n willi n g t o st o p alc o h ol c o ns u m pti o n 4 8 h o urs pri or t o eac h a d missi o n t o t he 
C R U, a n d w hile resi de nt at t he C R U. At all ot her ti mes, partici pa nts m ust a gr ee t o 
c o ns u me n o m ore t ha n 2 u nits per da y 
2 7.  Are s m o kers of m ore t ha n 1 0 ci garettes or e- ci gar ettes, or 3 ci gars or 3 pi pes, per da y 
a n d are u n a ble t o r efr ai n fr o m s m o ki n g w hile r esi de nt at t he C R U 
2 8.  C o ns u me e x cessi ve a m o u nts of c offee, tea, c ola, or ot her caff ei nate d be v era ges per 
da y, or ar e u n willi n g t o st o p caff ei ne c o ns u m pti o n 4 8 h o urs pri or t o a d missi o n a n d 
w hil e resi de nt at t he C R U. E x cessi ve a m o u nt is defi ne d as gr eater t ha n 6 s er vi n gs 
( 1  ser vi n g is a p pr o xi matel y e q ui val e nt t o 1 2 0 m g of caffei ne). 
2 9.  Ar e u na ble t o c o ns u me a sta n dar d meal.  
3 0.  C urre ntl y us e or s h o w e vi de nce of s u bsta n ce a b us e (i ncl u di n g alc o h ol a b us e) or 
de pe n de n ce wit hi n t he past 6 m o nt hs base d o n me dical hist or y at scree ni n g visit 
3 1.  I n a bilit y t o c o m pl y wit h t he dietar y r e gi me n of t he C R U  
3 2.  Are Lill y e m pl o yees or are a n e m pl o yee of a n y t hir d  part y i n v ol ve d i n t he st u d y w h o 
re q uire e x cl usi o n of t heir e m pl o yees 
3 3.  Are i n vesti gat or site pers o n nel directl y affiliate d wit h t his st u d y a n d/ or t heir i m me diate 
fa milies. I m me di ate fa mil y is defi ne d as a s p o us e, pare nt, c hil d, or si bli n g, w het her 
bi ol o gical or le gall y a d o pte d 
3 4.  I n t he o pi ni o n of t h e i n vesti gat or or s p o ns or, ar e u ns uita ble f or i ncl usi o n i n t he st u d y 
5 . 3 .  L i f e s t y l e  C o n s i d e r a t i o n s  
T hr o u g h o ut t he st u d y, partici pa nts ma y u n d er g o me dical assess me nts a n d re vie w of c o m plia nce 
wit h re q uire me nts bef ore c o nti n ui n g i n t he st u d y. 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
235.3.1. Meals and Dietary Restrictions
During the confinement period, participants will consume only food and beverages that are 
provi ded to them  by the CRU staff. Standard meals (e.g., breakfa st, lunch, dinner, and snack) 
will be provided to the participants while resident at the CRU.
Selpercat inib will be dosed in the fasted state on Days 1, 8, and 15. On these dosing occasions, 
the participants will be fasted overnight (at least 10 hours) pri or to dosing and refrain fro m 
consuming water fro m 1 hour predose until 2 hours postdose, excluding the amount of water 
consumed at dosing. Food is allowed fro m 4 hours postdose. At all other times during the study , 
participants m ay consume water ad libitu m. 
5.3.2.
Caffeine, Alcohol, and Tobacco
Parti cipants will abstain from ingest ing caffeine -or xanthine -containing products (e.g., coffee, 
tea, cola drinks, and chocolate) for 48 hours prior to admissio n unt il after discharge from the 
study .
Parti cipants will ab stain fro m alcoho l for 48 prior to admissio n unt il after discharge from the 
study .
Parti cipants who use tobacco products will be instructed that use of nicotine -containing products 
(including nicotine patches) will not be permitted while they are in the cl inical unit.
5.3.3. Activity
Parti cipants w ill abstain from strenuous exercise for 48 hours before each blood collect ion for 
clinical laboratory  tests. Parti cipants m ay parti cipate i n light recreational act ivities during the 
study  (e.g., watching televisio n, read ing).
5.4. Screen Failures
Screen failures are defined as part icipants who consent to participate in the clinical study  but are 
not subsequently assigned to study  interventi on. 
Individuals who do not meet the criteria for participation in this study  (screen failure) may notbe 
rescreened. Repeating o f laboratory  tests during the screening period or repeating screening tests 
to com ply wit h the protocol -designated screening period does not constitute rescreening.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
246. Study Intervention (s) and Concomitant Therapy
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to /used by a study  parti cipant 
according to the study  protocol .
6.1. Study Intervention(s) Administered
Table JZJU. 1.Study Interventions Administered
ArmName Capsule Ready touse PFOS
Study Intervention Selpercatinib Selpercatinib Selpercatinib
Dosage Formulation Capsule Suspension Suspension
Unit dose 
strengths/Dosage Levels1 20-mg capsule 20 mg/mL 20 mg/mL
Route of Administration Oral Oral Oral
Dosing Instructions 1capsule taken 
on Day  1, 8, or 15, 
according to the 
randomization schedule1 mL taken 
on Day  1, 8, or 15, 
according to the 
randomization schedule1 mL taken 
on Day  1, 8, or 15, 
according to the 
randomization schedule
Abbreviations: PFOS = powder for oral suspension.
6.1.1. Administration Details
A single oraldose of selpercat inib 20 mg will be administered in the morning of Day s 1, 8, 
and15. Capsules and suspensio n of selpercat inib will be administered w ith approximately 
240m L of room -temperature water . All doses will be administered while in a sitting posi tion. 
Parti cipants will not be allowed to lie supine for 2hours after dosing, unless clinically indicated 
or for study  procedures.
Selpercat inib capsules should be swallowed who le. Parti cipants shoul d not break , empty, or 
chew the capsules .
Further instructions will be provi ded.
On dosing days, participants will adhere to meal restrict ions as outlined in Sect ion
 5.3.1 .
6.2. Preparation , Handling , Storage , and Accountability
1.The invest igator or designee must confirm appropriate storage conditions have been 
maintained during transit for all study  intervent ion rece ived and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2.Only participants enro lled in the study  may receive study  intervent ion. Only authori zed 
study  personnel may supply , prepare, or administer study  intervent ion. All st udy 
intervent ion must be stored in a secure, environmentally controlled, and mo nitored 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
25(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h access 
limited to the investigator and authorized study  personnel .
3.The invest igator or authorized study  personnel are responsible for study  interventi on 
accountabilit y, reconciliat ion, and record maintenance (i .e., recei pt, reconciliat ion, and 
final disposit ion records).
4.Further gui dance and information for the final disposit ion of unused st udy interventi ons 
are provided in the study  reference manual .
Note: i n some cases, sites may destroy  the m aterial if the evaluator has verified and documented 
that the site has appropriate facilit ies and written procedures to dispose of clinical materi als.
Samples o f the specific batches o f selpercat inib used in the study will be retained; details will be 
provi ded separately .
6.3. Measures to Minimize Bias: Randomization and Blinding
This is an open -label study . There i s no bi as as the primary  endpoint is PK and object ive in 
measure.
Parti cipants will be assigned a unique number (randomizat ion number) on Day  1. The 
rando mizat ion number encodes the participant’s assignment to be dosed with either the capsule, 
RTU suspensio n, or PFOS on Days 1, 8, and 15,according to the randomizat ion schedule 
generated prior to the study  by the Stati stics Departm ent at Covance.
6.4. Study Intervention Compliance
Participants are dosed at the site andwill receive study  intervent ion directly from the investigator 
or desi gnee, under medical supervisio n. The date and time of each dose administered in the clinic 
will be recorded in the source documents and recorded in the electroni c case report form ( eCRF ). 
The dose of study  intervent ion and study  parti cipant i dentificat ion will b e confirmed at the time 
of dosing by  a member of the study  site staff other than the person administering the study  
intervent ion. Study  site personnel will examine each participant’s mouth to ensure that the study  
intervent ion was ingested.
When the indivi dual dose for a participant is prepared from a bulk supply, the preparation of the 
dose will be confirmed by a second member of the study  site staff. 
6.5. Dose Modification
Dose m odificat ion will not be permitted in this study .
6.6. Continued Access to Study Intervention After the End of the Study
Selpercat inib will not be made available to participants after complet ion of the study .
6.7. Treatment of Overdose
For the purposes of this study , an overdose of selpercatinib is considered as any  dose higher than 
the dos e assigned. There is no specific antidote for selpercat inib.
In the event of an overdose, the invest igator/treating physician shoul d:
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
261.Contact the medical monitor immediately .
2.Closely  monitor the parti cipant for any  AEs/serious adverse events ( SAE )and laboratory  
abnorm alities until study  intervent ioncan no l onger be detected systemically  (at least 5
days).
3.Docum ent the quanti ty of the excess dose as well as the duration of the overdose in the 
eCRF.
Decisio ns regarding dose interruptions will be ma de by  the invest igator in consultat ion with the 
medical mo nitor based on the clinical evaluat ion of the participant.
6.8. Concomitant Therapy
Any medicat ion or vaccine (including over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the study  must be recorded along wit h:
a.Reason for use
b.Dates of administration including start and end dates
c.Dosage information including dose and frequency for concomitant thera py of special  
interest
The medical monitor shoul d be contacted if there are any  questi ons regarding concomitant or 
prior therapy .
Parti cipants m ust abstain from  taking prescript ion or nonprescript ion drugs (including vitamins 
and dietary  or herbal suppleme nts) wi thin 14days before the start of study  intervent ion unt il 
discharge from  the study .
Acetaminophen , atdoses of ≤2grams/24 hours , is permitted for use at the discretion of the 
investigator for the treatment of headache, etc . Contraceptive medicat ionis permitted as per the 
contraception requirements ( Appendix 4 [Secti on10.4]), and hormone -replacement therapy  is 
also allowed.
Other medication may be considered on a case -by-case basis by the investigator in consultation 
with the Lilly clinical pharmaco logist (CP)/clinical research physician (CRP), or designee.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
277. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Parti cipants discont inuing from the study  or study  intervent ion prem aturely  for any reason 
shoul d com plete AE and other early discontinuat ion procedures as per the SoA (Section 1.3). 
Discontinuati on of  the study  as a who le is described in Appendix 1 (Secti on10.1).
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a participant to perm anent ly discont inue study  
intervent ion. If study  intervent ion is permanent ly discontinued, the participant will remain in the 
study  to be evaluated for safet y. See the S oA for dat a to be collected at the time of 
discontinuat ion of study  interventi on and discharge fro m the study ,and for any  further 
evaluat ions that need to be com pleted.
7.1.1. Liver Chemistry Stopping Criteria
Study  intervent ion will be discontinued for a participant if liver chemistry  stopping cri teria are 
met.
Phase 1 Liver Chemistry Stopping Algorithm
Abbreviations: ALT = alanine transaminase; INR = international normalized ratio; SAE = serious adverse event; 
ULN = upper limit of normal.
Liver Safety : Suggested Actions and Fo llow-up Assessments can be found in Appendix 6 
(Secti on10.6).Continue Study Treatment 
Discontinue Study Treatment 
*INR value not applicable to subjects on anticoagu lants ALT ≥3xULN No
Yes
Must refer to Liver Safety Required Actions and Follow up Assessm ents  section in the Appendix
Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measured*i D 
! 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
287.1.2. QTc Stopping Criteria
A participant who me ets ei ther bulleted criterio n following single ECG assessment should have 
ECG repeated. If the participant still meets either bulleted criterion they will be withdrawn from  
the study .
QTc, QTcB, or QTcF >500 msec
Change from baseline: QTc >60 msec
If a clinically significant finding is ident ified (including, but not limited to changes fro m baseline 
in QTcBor QTcF )after enrollment, the investigator or qualified designee will determine if the 
participant can continue in the study  and if any change i n part icipant management is needed. 
This review o f the ECG printed at the time of co llection must be documented. Any new 
clinically relevant finding should be reported as an AE.
See the SoA for data to be collected at the time of intervent ion discontinuat ion and discharge 
from the study ,and for any  further eval uations that need to be completed.
7.2. Participant Discontinuation/Withdrawal from the Study
A participant may withdraw fro m the study : 
at any  time at his/her own request 
at the discretion of the inve stigator for safet y, behavi oral, com pliance, or administrative 
reasons
if the participant beco mes pregnant during the study
if enro lledin any other clinical study  involving an investigat ional product or enroll edin 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
if the participant, for any  reason, requi res treatm ent wi th another therapeuti c agent that 
has been demonstrated to be effect ive for treatm ent of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent.
Discontinuati on is expected to be uncommo n.
At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, a s shown in the S oA. See SoA for data to be collected at the time of study 
discontinuat ion and for any  further evaluat ions that need to be completed . The participant will be 
perm anent ly discont inued fro m both the study  intervent ionand the study  at that tim e.
If the participant withdraws consent for disclosure of future informat ion, the sponsor may  retain 
and cont inue to use any data collected before such a withdrawal o f consent. If a participant 
withdraws fro m the study , he/she may  request destructi on of  any sam ples taken and not tested, 
and the invest igator must document this in the site study records.
7.3. Lost to Follow -up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact ed by  the study  site. Si te personnel or desi gnee are 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
29expected to m ake diligent attempts to contact participants who fail to return for a scheduled visit 
or were otherwise unable to be fo llowed up by the site.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
308. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA (Secti on 1.3). 
Immediate safet y concerns should be discussed wit h the sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  interventi on.
Adherence to the study  design requi rements, including those specified in the SoA, is 
essent ial and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potential 
participants m eet all eligibilit y criteria. The invest igator will maint ain a screening log to 
record details o f all participants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
8.1. Efficacy Assessments
Not applicable to this study .
8.2. Safety Assessments
Planned time points for all safet y assessments are provided in the SoA (Section 1.3).
8.2.1. Physical Examinations
Physical examinat ions should be conducted according to the SoA ( Section 1.3). 
A fullphysical examinat ion will include, at a minimum, assessments of the 
cardi ovascular, respi ratory , gastrointestinal ,and neurol ogical systems. Hei ght and wei ght 
will also be measured and recorded.
Invest igators should pay special attention to clinical signs related to previous serious 
illnesses.
8.2.2. Vital Signs
For each participant, vi tal signs m easurements shoul d be condu cted according to the SoA
(Secti on1.3).
Blood pressure and pulse rate should be measured singly after at least 5 minute s supine. For each 
individual participant , the same cuff size should be used throughout the study  for the 
meas urements of blood pressure. The cuff should be attached to the participant’s dominant arm.
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms. Where orthostatic measurements are requi red, participants shoul d be 
supine for at least 5 minutes and then participants will stand, and standing blood pressure will be 
measured after 2 minutes , but no longer than 3 minutes. If the participant feels unable to stand, 
supine vital signs only  will be collected. Addit ional vital signs m ay be m easured if warranted.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
318.2.3. Electrocardiograms
For each participant, single 12-lead ECG s will be obtained as outlined in the SoA (see 
Secti on1.3). Refer to Section 7for QTc withdrawal criteria and any addit ional QTc
readings t hat may be necessary .
Electrocardiograms must be recorded before collecting any blood samples. Participants must be 
supine for approximately  5 to 10 minutes before ECG collect ion and rem ain supine but awake 
during ECG collect ion. Electrocardi ogram s may  be obtained at addit ional times, when deemed 
clinically necessary . All ECGs recorded shoul d be stored at the invest igational site.
Electrocardiograms will be interpreted by  the investi gator at the si te as soon after the time of 
ECG collect ion as possible, and ideally while the participant is still present, to determine whether 
the participant meets entry  criteria at the relevant visit(s) and for immediate participant 
management, should any clinically relevant findings be identified. 
If a clinically significan t finding is i dentified (including, but not limited to, changes in QT/QTc 
interval  from baseline) after enrollment, the investigator will determine if the participant can 
continue in the study . The investigator, or qualified designee, is responsible for de termining if 
any change in part icipant management is needed and must document his/her review o f the ECG 
printed at the time of co llection. Any new clinically relevant finding should be reported as an 
AE.
8.2.4. Clinical Safety Laboratory Tests
See Appendix 2 (Secti on10.2)for the list of clinical laboratory  tests to be performed and 
to the SoA for the timing and frequency.
The invest igator must review the laboratory  report, docum ent thi s review, and record any  
clinically relevant changes occurring during the study  in the AE section of the eCRF. The 
laboratory  reports m ust be filed wit h the source documents.
All laboratory  tests wi th values considered c linically significantly abnormal during 
participat ion in the study after the last dose of study intervent ion shoul d be repeated until 
the values return to normal or baseline or are no longer considered clinically significant 
by the investigator or medical monitor.
If such values do not return to normal/baseline wit hin a peri od of  time judged 
reasonable by the invest igator, the etio logy shoul d be ident ified, and the sponsor 
notified.
All protocol -requi red laboratory  assessments, as defined in Appendix 2 
(Section10.2), must be conducted in accordance wit h the l aboratory  manual  and 
the SoA.
If laboratory  values fro m non-protocol  specified l aboratory  assessments performed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are considered 
clinically significant by  the investi gator (e .g
., SAE or AE), then the results must be recorded in 
the eCRF.
8.2.5. Pregnancy Testing 
Where a pplicable , pregnancy tests will be performed as outlined in the SoA (see Section 1.3).
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
328.2.6. Safety Monitoring
The Lilly CPor CRP/sci entist will mo nitor safet y data throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures. The Lilly CPor 
CRP will periodically review the fo llowing data:
trends in safety  data
laboratory  analy tes including hematol ogy and chemistry
When appropriate, the Lilly CPor CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist.
8.2.6.1. Hepatic Safety
Close hepat ic monitoring
Laboratory tests (Appen dix6 [Secti on10.6]), including AL T, AST , alkaline phosphatase ( ALP), 
total bilirubin ( TBL ), direct bilirubin , gamma- glutamyl  transf erase , and creat inekinase , shoul d 
be repeated within 48 to 72 hours to confirm the abnormalit y and to determine if it is increasing 
or decreasing, if one or more of these condit ions occur:
If a participant with baseline 
resul ts of ... develops the fo llowing elevati ons:
ALT or AST <1.5 ×upper 
limit of normal ( ULN )ALT or AST ≥3× ULN
ALP <1.5 ×ULN ALP ≥2×ULN
TBL <1.5 ×ULNTBL ≥2×ULN (except for patients with 
Gilbert’s syndrome)
ALT or AST ≥1.5 ×ULN ALT or AST ≥2×baseline
ALP ≥1.5 ×ULN ALP ≥2×baseline
TBL ≥1.5 ×ULNTBL ≥2×baseline (except for patients with 
Gilbert’s syndrome)
If the abnormalit y persists or worsens, clinical and laboratory  monitoring and evaluat ion for 
possible causes of abnormal liver tests should be init iated by  the invest igator in consultat ion with 
the Lilly -designated m edical mo nitor. At a minimum, this eval uation shoul d include physical 
examinat ion and a thorough medical history , including symptom s, recent illnesses (for example, 
heart failure, systemic infect ion, hypotension, or seizures), recent travel, history  of concomi tant 
medicat ions (including over -the-counter), herbal and dietary  supplements, and history  of alcohol  
drinking and other substance abuse. 
Initially, monitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipant’s clinica l condit ion and hepat ic biochemical tests. 
Subsequently, the frequency  of monitoring m ay be l owered to once every  1 to 2 weeks, if the 
participant’s clinical condit ion and laboratory results stabilize. Monitoring of ALT, AST, ALP, 
and TBL should continue u ntil levels norm alize or return to approximate baseline levels.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
33Com prehensive hepatic evaluation 
A comprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
one or m ore of these condit ions occur:
If a participant with b aseline 
resul ts of... develops the fo llowing elevat ions:
ALT or AST <1.5 ×ULN ALT or AST ≥3× ULN wi th hepat ic signs/symptoms*, or
ALT or AST ≥5×ULN
ALP <1.5 ×ULN ALP ≥3×ULN
TBL <1.5 ×ULN TBL ≥2×ULN (except for patients with Gilbert’s syndro me)
ALT or AST ≥1.5 ×ULN ALT or AST ≥2×baseline wit h hepat ic signs/symptoms*, or
ALT or AST ≥3×baseline
ALP ≥1.5 ×ULN ALP ≥2×baseline
TBL ≥1.5 ×ULN TBL ≥1.5 ×baseline (except for patients with Gilbert’s 
syndro me) 
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, 
and/o r eosinophilia >5%.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for prothrombin t ime/internat ional normalized ratio ; 
tests for viral hepatit is A, B, C, or E; tests for autoimmune hepat itis; and an abdo minal imaging 
study  (for example, ul trasound or computed tomography scan). 
Based on the participant ’shistory  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tes ts for hepati tis D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine toxico logy screen, W ilson’s disease, blood alcohol levels, urinary  ethyl  glucuroni de, and 
serum  phosphat idylethano l. Based on the circ umstances and the invest igator ’s assessment of the 
participant ’s clinical condit ion, the invest igator should consider referring the participant for a 
hepatol ogist or gastroenterologist consultation, magnet ic resonance cho langiopancreatography , 
endoscopi c retrograde cholangiopancreatography , cardi ac echocardi ogram , or a liver biopsy . 
Additional hepatic data collection (hepatic safety eCRF) in study participants who have 
abnormal liver  tests during the study:
Addit ionalhepatic safet y data collect ion in hepatic safety eCRFs shoul d be perform ed in study  
participants who meet 1 or more of the fo llowing 5 condi tions:
1.Elevat ion of serum AL T to ≥5× ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5 × ULN)
In parti cipants wi th baseline ALT ≥1.5 ×ULN, the thresho ld is ALT 
≥3×baseline on 2 or more consecut ive tests
2.Elevated TBL  to ≥2×ULN (if baseline TBL  <1.5 ×ULN) (except for cases of known 
Gilbert ’s syndrom e)
In parti cipants wi th baseline TBL  ≥1.5 × ULN, the thresho ld should be TBL  
≥2×baseline
3.Elevat ion of serum ALP to ≥2×ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5 ×ULN)
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
34In parti cipants wi th baseline ALP ≥1.5 ×ULN, the thresho ld is ALP ≥2× baseline 
on 2 or more consecutive blood tests
4.Hepati c event consi dered to be an SAE
5.Discontinuati on of  study  drug due to a hepati c event 
NOTE : the interval between the 2consecutive blo od tests should be at least 2 day s.
8.3. Adverse Events ,Serious Adverse Events , and Product Complaints
Product Complaint s are covered in Sect ion 8.3.3 .
The definit ions of the fo llowing events can be found in Appendix 3 (Section 10.3):
AEs
SAEs
Product complaints (PCs)
These events will be reported by  the parti cipant (or, when appropriate, by  a caregiver, surrogate, 
or the participant's legally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the sedefinit ionsand remain responsible for fo llowing up events that 
are seri ous, considered related to the study  intervent ion or study  procedures, or t hat caused the 
participant to di scont inue the study  intervent ion/study  (see Section 7).
Care will be taken not to introduce bias when detecting events . Open -ended and non -leading 
verbal quest ioning of the participant is the preferred method to inquire about event occurrences.
8.3.1. Timing and Mechanism for Collecting Events
Thistable describes the timing, deadlines ,and m echanism for collect ing events.
Event Collection 
StartCollection 
StopTiming for Reporting 
to Sponsor or 
DesigneeMechanism for 
ReportingBack -up 
Method of 
Reporting
Adverse Event
AE Signing of 
the ICFParticipation 
in study has 
endedAs soon as possible 
upon site awarenessAE eCRF N/A
Serious Adverse Event
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
35Event Collection 
StartCollection 
StopTiming for Reporting 
to Sponsor or 
DesigneeMechanism for 
ReportingBack -up 
Method of 
Reporting
SAE and SAE 
updates –prior 
to start of study 
interventio n and
deemed 
reasonably 
possibly related 
with study 
proceduresSigning of 
the ICFStart of 
interventio nWithin 24 hours of 
awarenessSAE paper form SAE paper 
form
SAE andSAE 
updates –after 
start of study 
interventio nStart of 
interventio nParticipation 
in study has 
endedWithin 24 hours of 
awarenessSAE paper form SAE paper 
form
SAE –after 
participant’s 
study 
participation has 
ended andthe 
investigator 
becomes awareAfter 
participant’s 
study 
participation 
has endedN/A Promptly SAE paper form N/A
Pregnancy
Pregnancy in 
female 
participants and 
female partners 
of male 
participantsAfter the 
start of study 
interventio nAt least 
5terminal 
half-lives or 
30 days after 
the last dose , 
whichever is 
longerWithin 24 hours (see 
Section 8.3.2)SAE paper form SAE paper 
form
Product Complaints
PCassociated 
with an SAE or
might have led 
to an SAEStart of study 
interventio nEnd of study 
interventio nWithin 24 hours of 
awarenessProduct Complaint 
formN/A
PC not 
associated with 
an SAEStart of study 
interventio nEnd of study 
interventio nWithin 1 business day 
of awarenessProduct Complaint 
formN/A
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
36Event Collection 
StartCollection 
StopTiming for Reporting 
to Sponsor or 
DesigneeMechanism for 
ReportingBack -up 
Method of 
Reporting
Updated PC 
information— — As soon as possible 
upon site awarenessOriginally 
completed Product 
Complaint form 
with all changes 
signed and dated by 
the investigatorN/A
PC (if 
investigator 
becomes aware)Participation 
in study has 
endedN/A Promptly Product Complaint 
form
8.3.2. Pregnancy
Collection of pregnancy information
Male participants w ith partners who become pregnant
●The invest igator will attempt to collect pregnancy informat ion on any male 
participant’s female partner who beco mes pregnant while the male participant is 
in this study . This applies only  to m ale parti cipants who receive study  
intervent ion.
●After obtaining the necessary  signed informed consent from the pregnant female 
partner direct ly, the invest igator will record pregnancy informat ion on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the 
partner’s pregnancy .The female partner will also be fo llowed to determine the 
outcom e of the pregnancy . Informati on on the status of the m other and child will 
be forwarded to the sponsor. Generally, the fo llow-up will be no longer than 6 to 
8weeks following the estimated delivery date. Any terminat ion of the pregnancy 
will be reported regardless of gestati onal age, fetal status (presence or absence of 
anomalies),orindication for the procedure. 
Female participants who become pregnant
●The invest igator will co llect pregnancy information on any female participant 
who beco mes pregnant while part icipating in this study . The init ial information 
will be recorded on the appropriate form and submitted to the sponsor within 24 
hours of learning of a parti cipant's pregnancy . 
●The parti cipant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will co llect fo llow-up inform ation on the participant and the neonate 
and the information will be forwarded to the sponsor. Generally, fo llow-up will 
not be required for longer than 6 to 8 weeks bey ond the estimated delivery  date. 
Any terminat ion of pregnancy  will be reported ,regardless of gestati onal age, fetal 
status (presence or absence of anomalies) ,or indication for the procedure.
CONFIDENTIAL  Protocol number J2G- MC-JZJU (b)  
 37 ● While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
● A spontaneous abortion (occurring at <20 weeks gestational age) or still birth 
(occurring at ≥20 weeks gestational age) is always considered to be an SAE and 
will be reported as such.  
● Any poststudy pregnancy- related SAE considered reasonably related to the study 
intervention by the investigator will be reported to the sponsor as described in 
protocol Section 8.3.1. While the investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE through spontaneous reporting. 
● Any female participant who becomes pregnant while participating in the study will discontinue study intervention. If the participant is discontinued from the 
study, follow the standard discontinuation process and continue directly to the follow-up phase. The follow-up on the pregnancy outcome should continue 
independent of intervention or study discontinuation. 
Prior to continuation of study intervention following pregnancy, the following must occur: 
● The sponsor and the relevant institutional review board ( IRB)/independent ethics 
committee ( IEC) give written approval. 
● The participant gives signed informed consent. 
● The investigator agrees to monitor the outcome of the pregnancy and the status of the 
participant and her offspring. 
8.3.3. Product Complaints  
A product complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, durability, reliability, safety, effectiveness , or performance of a 
study intervention.  The sponsor collects PCs on investigational products and drug delivery systems used in clinical 
studies in order to ensure the safety of study participants, monitor quality, and to facilitate process and product improvements. 
Participants  will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigation al product so that the situation can be assessed. 
NOTE: AE s/SAE s that are associated with a product complaint will also follow the processes 
outlined in Sectio n 8.3.1 and Appendix 3 (Section  10.3) of t he protocol. 
8.4. Pharmacokinetics  
● Venous blood samples of approximately 2 mL will be collected for measurement 
of plasma  concentrations of selpercatinib as specified in the SoA  (Section 1.3).  
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
38●A maximum of 3samples m ay be collected at additional t ime po ints during the 
study  if warranted and agreed upon between the investigator and the sponsor. The 
timing of sampling may be altered during the course of the study  based on newly  
available data ( e.g., to obtain data closer to the time of peak plasma 
concentrations) to ensure appropriate monitoring. 
●Instructi ons for the collect ion and handling of bio logical samples will be provided 
by the sponsor. The actual date and time (24 -hour clock time) of each sample will 
be recorded.
8.5. Pharmacodynamics
Pharmacodynamic parameters a re not evaluated in this study .
8.6. Genetics
A blood OR saliva sample for DNA i solation will be co llected fro m participants. 
See Appendix 5 (Secti on10.5)for information regarding genetic research and Appendix 1 
(Secti on10.1)for details about sample retention and custody . 
8.7. Biomarkers
Biomarkers are not eval uated in thi s study .
8.8. Immunogenicity Assessments
Not applicable for this study .
8.9. Health Economic s
This sect ion is not applicable for this study .
8.10. Product Acceptability and Palatability Assessments
The parti cipant will be asked to provide responses to questions designed to assess the
acceptabilit y and palatabilit y of the RTU suspension . The questionnaire will assess the 
participant ’s experi ence relating to the taste, smell, and aftertaste in the oral cavit y.
The quest ionnaire will be co mpleted by  the participant immediately after administration of the
RTU suspensio nand PFOS formulat ions.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
399. Statistical Considerations
9.1. Statistical Hypotheses
The primary  object ive will be evaluated to assess the relative bioavailabilit y of the RTU
suspension and drug -in-bottle formulations co mpared to the commercial formulat ion (capsule) .
9.2. Analyses Sets
The fo llowing popul ations are defined:
Population Description
Entered All participants who sign the ICF.
Safety All enrolled participants who take at least 1 dose of selpercatinib, whether or 
not they completed all protocol requirements .
Pharmacokinetic Analysis All participants who received at least 1 dose of selpercatinib andhave 
evaluable PK data.
9.2.1. Study Participant Disposition
A detailed description o f participant disposi tion will be provided at the end of the study .
9.2.2. Study Participant Characteristics
The part icipant’s age, sex, and other demographic characterist ics will be recorded and 
summarized.
9.2.3. Treatment Compliance
The date and time of dosing will be recorded and listed.
9.3. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y of the sponsor or its designee. 
Pharmacokinet icanalyses will be conducted on data fro m all participants who received at least 
1dose of selpercatinib and have evaluable PK data. 
Safety analys es will  be conducted for all enrolled participants who received at least 1 dose of 
selpercat inib, whether or not they  com pleted all  protocol  requi rements. 
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.
9.3.1. S afety Analyse s
All invest igational product and protocol procedure AEs will be listed, and if the frequency o f 
events allows, safet y data will be summarized using descript ive methodol ogy. 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
40The incidence of AEs for each treatment will be presented by  severi ty and by assoc iation with 
investigat ional product as perceived by the investigator. Adverse events reported to occur prior 
toenrollment will be dist inguished fro m those reported as new or increased in severit y during the 
study . Each AE will  be classified by the most su itable term fro m the medical regulatory  
dictionary. 
The number of invest igational product related SAEs will be reported.
9.3.1.1. Statistical Evaluation of Safety
Safety param eters that will be assessed include safety  laboratory  parameters, vi tal signs, and 
ECG pa rameters. Addit ional analysis will be performed if warranted upon review of the data.
9.3.2. Pharmacokinetic Analyses
9.3.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates will be calculated by standard nonco mpart mental methods. 
The primary  PK param eters f or analysis of selpercatinib will be: maximum observed drug 
concentration ( Cmax),area under the concentration vers us time curve fro m time zero to i nfinity 
(AUC [0-∞]) , area under the concentration versus t ime curve from t ime zero to time t, where t is 
the last time po int with a measurable concentration (AUC 0-tlast),andtime to C max(tmax). 
Other noncompartmental parameters, such as terminal half -life ( t1/2), apparent total body  
clearance of drug cal culated after extravascular administrati on, and apparent vo lumeof 
distribut ion during the terminal phase after extravascular administration, may be reported as 
appropriate.
9.3.2.2. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameters will be evaluated to estimate relative bioav ailabilit y. For the 
primary  analysis, l og-transform ed C max,AUC (0-∞), and AUC0 -
tlastwill be evaluated in a linear 
mixed -effect m odel with fixed effects for formulatio n, peri od, and sequence , and a random  effect 
for subject. The treatment differences will be back -transformed to present the ratios of geometric 
means and the correspondi ng confidence intervals ( CIs).
For secondary  analysis, t he tmaxwill be analyzed using a Wilco xon signed rank test. Estimates of 
the median difference based on the observed medians, 90% CIs ,and p -values fro m the Wilcoxon 
test will be calculated. Pharmacokinet ic parameters will be summarized using descript ive 
statist ics.
9.3.3. Pharmacodynamic Analyse s
Not applicable for this study .
9.3.4. Pharmacokinetic/Pharmacodynamic Analyses
Not applicable for this study .
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
419.4. Interim Analys is 
No interim analyses are planned for this study . If an unplanned interim analysis is deemed 
necessary  for reasons other than a safet y concern, the protocol must be amended.
9.5. Sample Size Determination
Up to approximately  42 partici pants will be enrolled to ensure that at least approximately  
36participants complete the study .The sample size for this study  is just ified based on a 
preci sion for the ratio of geometri c means and i t is represented by  the half -width of the 90% CI 
of the point estimate on the logarithmic scale. Based on an intra- subject variabilit y of 70%
(LOXO- RET -19075) , with a probabilit y of 90%, a 90% CIfor the ratio of the geometric means 
for Cmaxand AUC will be obtained wit h a precisio n about 0.288 in the log scale, which 
corresponds to approximately 0. 334in the natural scale .
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
4210. Supporting Documentation and Ope rational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
●This study  will be conducted in accordance wit h the protocol and with the 
following:
○Consensus ethical principles derived from international guidelines including 
the Decl aration of Helsinki and Council for International Organizations of 
Medical Sciences Internat ional Ethi cal Guidelines
○Applicable I nternat ional Council for Harmonisation (I CH)Good Clinical 
Practi ce (GCP) Gui delines
○Applicable laws and regulations
● The protocol, protocol amendments, ICF, IB, and other relevant documents ( for 
example , advertisements) must be submitted to an IRB/IEC by  the invest igator 
and reviewed and approved by  the IRB/IEC before the study is initiated.
●Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study  design, except for changes 
necessary  to eliminate an immediate hazard to study  parti cipants.
●Protocol s and any substantial amendments to the protocol will require healt h 
authori ty approval  prior to ini tiation except for changes necessary  to eliminate an 
immediate hazard to study  parti cipants .
●The invest igator will be responsible for the fo llowing:
○Provi ding wri tten summari es of the status of the study  to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by the IRB/IEC
○Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required 
by IRB/IEC pr ocedures
○Provi ding oversight of study  conduct for parti cipants under thei r responsibilit y 
and adherence to requirements of 21 C ode of Federal Regulat ions (C FR), ICH 
guidelines, the IRB/IEC, European regulat ion 536/2014 for clinical studies (if 
applicable ), and all  other applicable l ocal regulat ions
●Invest igator sites are compensated for participat ion in the study as detailed in the 
Clinical TrialAgreement .
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
4310.1.2. Informed Consent Process
●The invest igator or his/her representative will explain the nature of the study , 
including the risks and benefit s,to the participant and answer all questi ons 
regarding the study .
●Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants 
will be required to sign a statement of informed consent that meets the 
requi rements of 21 CFR 50, local regulations, ICH guidelines, privacy  and data 
protecti on requi rements, where applicable, and the I RB/IEC or study center.
●The m edical  record m ust include a statem ent that wri tten inform ed consent was 
obtained b efore the parti cipant was enter ed in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.
●Parti cipants m ust be reconsented to the most current version of the ICF(s) during 
their parti cipat ion in the study .
●A copy  of the ICF(s) m ust be provi ded to the participant and is kept on file .
10.1.3. Data Protection
●Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant 
records ,datasets or tissue samples that are transferred to the sponsor will contain 
the identifier only; participant names or any  informat ion thatwould make the 
participant i dentifiable will not be transferred.
●The parti cipant must be inform ed that hi s/her personal  study -related data wi ll be 
used by the sponsor in accordance wit h local data -protecti on law. The level o f 
disclosure m ust al so be explained to the participant who will be required to give 
consent for his/her data to be used as described in the informed consent .
●The parti cipant m ust be inform ed that hi s/her m edical  records m ay be examined 
by Clinical Qualit y Assurance auditors or other authorized personnel appo inted by  
the sponsor, by  appropri ate IRB/IEC m embers, and by  inspectors from regulatory  
authori ties.
●The sponsor ha s processes in place to ensure data protection, informat ion securit y 
and data integrit y. These processes include appropriate contingency plan(s) for 
appropriate and timely  response in the event of a data securit y breach.
10.1.4. Dissemination of Clinical Study Dat a
Communication of Suspended or Terminated Dosing
If a decisio n is taken to suspend or terminate dosing in the trial due to safet y findings, this 
decisio n will be communicated by Lilly to all investigators (for example, by phone and/or email) 
as soon as possible. It will be a requirement that investigators respond upon receipt to confirm 
that they  understand the comm unicati on and have taken the appropriate action prior to further 
dosing any participants with study  intervent ion. Any invest igator not respon ding will be 
followed up by  Lilly personnel pri or to any  further planned dosing. If a dose is planned 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
44imminent ly, Lilly personnel will immediately, and continually, use all efforts to reach 
investigators until contact is made and instructions verified. 
Reports 
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publicly  available websites where required by  local law or regul ation. 
Data 
The sponsor does not proactively  share data from  Phase 1 clinical tri als. Req uests for access to 
Phase 1 clinical trial data are evaluated on a case -by-case basis taking into considerat ion the 
abilit y to anonymize the data and the nature of the data collected.
10.1.5. Data Quality Assurance
●All participant data relat ing to the study  will be recorded on printed or electronic 
CRF sunless transmitted to the sponsor or designee electronically  (for example , 
laboratory  data). The investigator is responsible for verifying that data entries are 
accurate and correct by  physically  or electronically signing the eCRF.
●The invest igator must maintain accurate documentation (source data) that 
supports the informat ion entered in the eCRF.
●The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, 
and regulatory  agency inspect ions and provi de direct a ccess to source data 
docum ents.
●Qualit y tolerance limits (QTLs) will  be pre defined to identify system atic issues 
that can impact participant safety  and/or reliabilit y of study  resul ts. These 
pre-defined parameters will be monitored dur ing the study  and important 
excursio ns from the QTLs and rem edial act ions taken will be summarized in the 
clinical study  report .
●Moni toring details describing strategy  (for example , risk-based init iatives in 
operati ons and qualit y such as risk management and mit igation strategi es and 
analyt ical risk- based mo nitoring), methods, responsibilit ies,and requi rements, 
including handling of nonco mpliance issues and monitoring techniques ,are 
provi ded in the Moni toring Pl an.
●The sponsor or designee is responsib le for the data management of this study  
includin g qualit y checking of the data.
●The sponsor assumes accountabilit y for acti ons delegated to other individuals 
(e.g., contract research organizat ions).
●Study  monitors will perform  ongoing source data veri fication to confirm that data 
entered into the e CRF by authorized site personnel are accurate, complete, and 
verifiable fro m source docum ents; that the safet y and ri ghts of  parti cipants are 
being protected; and that the study  is being conducted in accordan ce wi th the 
currently approved protocol and any other study  agreem ents, ICH GCP, and all 
applicable regu latory  requi rements.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
45●Records and documents, including signed ICFs, pertaining to the conduct of this 
study  must be retained by  the invest igator for the time period outlined in the 
Clinical Trial Agreement unless local regulat ions or inst itutional policies requi re a 
longer retention period. No records may be destroyed during the retention period 
without the wri tten approval  of the sponsor. No records may be transferred to 
another location or party  without wri tten notification to the sponsor .
●In addit ion, the sponsor or its representatives will periodically  check a sample of 
the participant data recorded against source documents at the study  site. The st udy 
may be audited by the sponsor or its representatives, and/or regulatory  agencies at 
any time. Invest igators will be given notice before an audit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of eCRF 
data. The invest igator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system. The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the eCRF .
Data collected via a sponsor -provided data capture system will bestored at a thirdparty . The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem .Prior to decommissio ning, the invest igator will receive an archiva l 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and electronic transfers will be provi ded to the invest igator 
for review and reten tion. Data will subsequent ly be transferred fro m the central  vendor to the 
sponsor data warehouse.
Data from co mplaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.6. Source Documents
●Source documents provide evidence for the existence of the participant and 
substant iate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
●Data reported on the CRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies 
must be explained. The invest igator may need to request previous medical records 
or transfer records, depending on the study . Also, current medical records must be 
available.
●Definition of what constitutes source data can be found in Section10.1.4 .
10.1.7. Study and Site Start and Closure
First Act of Rec ruitment
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
46The study  start da te is the date on which the clinical study  will be open for recruit ment of 
participants.
Study or Site Termination
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will  be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study site closure visi t has been perform ed.
The invest igator may init iate study site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
For study  termin ation:
● Discontinuati on of  further study  intervent ion developm ent.
For si te terminati on:
●Failure of the invest igator to comply wit h the protocol, the requirements of the 
IRB/IEC or local healt h authorit ies, the sponsor's procedures, or GCP guidelines
●Inadequate recruit ment (evaluated after a reasonable amount of time) of 
participants by  the invest igator
●Total  number of participants included earlier than expected .
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by the applicable 
regul atory  requi rements. The investigator shall prompt ly inform  the participant and shoul d assure 
appropriate participant therapy  and/or foll ow-up.
10.1.8. Publication Policy
In accordance with the sponsor’s publication po licy, the res ults of this study  will be submitted 
for publicat ion by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
4710.2. Appendix 2: Clinical Laboratory Tests
The tests detailed in the table below will be performed by the local laboratory .
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed in 
Secti on 5of the protocol.
Addit ional tests m ay be perform ed at any  time during the study  as determined necessary  
by the investigator or required by  local regulat ions.
Invest igators must document their review of thelaboratory  safety resul ts.
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate (total CO 2)
Mean cell volume Chloride 
Mean cell hemoglobin Calcium 
Mean cell hemoglobin concentration Phospho rus 
Leukocytes (WBC) 
PlateletsGlucose (random )
Creatine kinase
Differential WBC (absolute counts) of Blood urea nitrogen (BUN)
Neutrophils Uric acid 
Lymphocy tes Total Cholesterol, HDL -C, LDL-C
Monocytes Total protein
Eosinophils Albumin
Basophils Total bilirubin
Alkaline phosphatase (ALP)
Urinalysis a Aspartate aminotransferase (AST)
Specific gravity Alanine aminotransferase (ALT)
pH Creatinine
Protein
Glucose Ethanol testing b
Ketones Urine drug screen b
Bilirubin Hepatitis B surface antigen c
Urobilinogen Hepatitis C antibody c, d
Blood HIV c
Nitrite Pregnancy test e
Leukocyte esterase FSH (if applicable) c
Abbreviations: FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cell; 
WBC = white blood cell.
aPerformed by dipstick. Reflex microscopy to be performed if microscopy is abnormal.
bUrine drug screen and ethanol (urine or breath) level performed at screening, and may be repeated prior to 
admission to the Clinical Research Unit.
cPerformed at screening only.
dParticipants with a positive hepatitis C antibody test result can have a confirmatory hepatitis C RNA test.
eScreening and Day -1 only .
CONFID ENTIAL Protoc ol number J2G-MC-JZW(b) 
10.2.1. Blood Sampling Summar y 
This table summ arizes the approximate numb er of venipunct ures and blood volumes for all 
blood samp ling (scree ning, safety laborator ies, and bioanalytical assays) durin g the study. 
Protocol J2G-M C-JZJU Sam 
Blood Volum e per Numb e1 · of Blood Total Volum e 
Pm ose Sam le mL Sam Jes mL 
Screening testsa 45 45 
Clinica l laboratory testsa 12 7 84 "-------+----~ ~-----If---- ----+--- ---t 
Blood discard for cammla patency 1 
Gene tic sam le 
Total 260 
Total for clinical m oses 260 
a Additional samples may be draw n if needed for safety pmpose s. 
48 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
4910.3. Appendix 3: Adverse Events and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow- up, and 
Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a participant administered a 
pharmaceutical product and which does not necessarily have a causal relat ionship with 
the study  intervent ion. An AE can therefore be any unfavourable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or exacerbated)
temporally  associ ated wi th the use of a m edicinal (investigat ional) product, whether or 
not rel ated to the m edicinal (investigational) product .
Events Meeting the AE Definition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments ( for example , ECG, radi ological scans, vi tal signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the invest igator ( that is, not rel ated 
to progression of unde rlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ion detected or diagnosed after study  intervent ion administration even 
though it ma y have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose sshoul d be reported regardless of sequelae.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments thatare associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.
The disease/dis order being studi ed or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
Medical or surgical procedure ( for example , endoscopy , appendectomy ): the condi tion 
that leads to the procedure is the AE.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
50Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed :
d.Results in death
e.Is life -threatening
The term  life-threatening in the definit ion of serious refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.
f.Requires inpatient hospitalizatio n or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal or 
emergency ward (usually invo lving at least an overnight stay ) for observat ion and/or 
treatm ent that woul d not have been appropri ate in the physician’s office or outpatient 
setting. Co mplications that occur during hospitalization are AEs. If a co mplication 
prolongs hospitalizat ion or fulfills any other serious criteria, the event is serious. When 
in doubt as to whether hospi talizat ion occurred or was necessary , the AE shoul d be 
considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen 
from baseline is not considered an AE.
g.Results in persistent disability/incapacity
The t erm disabilit y means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea , influenza, 
and accidental trauma ( for example , sprained ankle) ,which may interfere wit h or 
prevent every day life f unctions but do not constitute a substant ial disruption.
h.Is a congenital anomaly/birth defect
Abnorm al pregnancy outcom es (e.g., spontaneo us abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
i.Other situations:
Medical or scient ific judgment should be exercised by the invest igator in deciding 
whether SAE reporting is appropriate in other situatio ns such as important medical 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
51events that may  not be immediately life- threatening or resul t in death or hospitalizat ion 
but m ay jeopardi ze the parti cipant or m ay require medical or surgical intervent ion to 
prevent one of the other outcomes listed in the abo ve definit ion. These events should 
usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias ,or 
convulsio ns that do not res ult in hospi talizat ion, or development of drug dependency or 
drug abuse.
10.3.3. Definition of Product Complaints
Product Complaint
A product complaint is any written, electronic, or oral communicat ion that alleges 
deficiencies related to the identit y, qualit y,durability , reliabilit y, safet y, effect iveness ,
or performance of a study interventi on.When the abilit y to use the study  intervent ion 
safely is impacted, the fo llowing are al so product com plaints:
oDeficiencies in labeling informat ion, and
oUse errors for device or drug-device combination products due to ergonomic 
design elements of the product.
Product complaints related to study  interventions used in clinical trials are collected in 
order to ensure the safet y of parti cipants, m onitor quali ty, and to facil itate process and 
product improvements.
Invest igators will instruct p articipants to contact the siteas soon as possible if he or she 
has a product complaint or problem wit h the study  interventionso that the situation can 
be assessed.
An event may meet th e definit ion of both a product complaint and an AE/SAE. In such 
cases, it should be reported as both a product complaint and as an AE/SAE.
10.3.4. Recording and Follow -Up of AE and/or SAE and Product Complaints
AE,SAE ,and Product Complaint Recording
When an AE/SAE /product com plaint occurs, i t is the responsibilit y of the investi gator 
to revi ew all  documentati on (for example , hospi tal progress notes, laboratory  reports, 
and diagnostics reports) related to the event.
The invest igator will then record all releva nt AE/SAE /product com plaint informat ion 
in the part icipant’s medical records, in accordance with the invest igator’s normal 
clinical practice . AE/SAE information is reported o n the appropri ateeCRF page and 
product complaint informat ion is reported on the P roduct Com plaint Form .
Note: An event may meet the definit ion of both a product complaint and an AE/SAE. 
In such cases, it should be reported as both a product complaint and as an AE/SAE.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
52It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to the sponsor or designee in lieu of completion of the eCRF page for AE/SAE 
and the Product Complaint Form for product complaints .
There m ay be instances when copies of medical  records for certain cases are requested 
by the s ponsor or desi gnee . In this case, all participant identifiers, with the except ion of 
the participant number, will be redacted on the copies of the medical records before 
submissio n to the sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .
Assessmen t of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during 
the study  and assign it to oneof the fo llowing categori es:
Mild: A type of adverse event that is usually  transient and m ay requi re only  minimal  
treatm ent or therapeutic intervent ion. The event does not generally interfere wit h usual 
activit ies o f daily living.
Moderate: A type of adverse event that is usually alleviated with addit ional specific 
therapeuti c intervent ion. The event interferes with usual act ivities o f daily living, 
causing disco mfort but poses no significant or permanent risk of harm to the research 
participant.
Severe: A type of adverse event that interrupts usual act ivities of daily living, or 
significant ly affects clinical status, or may  require intensive therapeut ic intervent ion. 
An AE that is assessed as severe should not be confused wit h anSAE. Severe is a 
category  utilized for rati ng the intensit y of an event; and both AEs and SAEs can be 
assessed as severe.
An event is defined as ‘serious’ when it meets at least oneof the predefined outcomes 
as described in the definit ion of an SAE, NOT when it is r ated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE. The investigator will use clinical judgment to 
determine the relat ionship .
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relat ionship, rather than a relat ionship cannot be 
ruled out.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the IB in his /her assessment.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
53For each AE/SAE, the invest igator must document in the me dical  notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has 
minimal informat ion to include in the init ial report to the sponsor or designee . 
Howe ver, it is very  important that the invest igator always make an assessment of 
causalit y for every  event before the init ial transmission of the SAE data to the sponsor 
or desi gnee .
The invest igator may change his/her opinio n of causalit y in light of fo llow-up 
inform ation and send a nSAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  
reporting requirements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by the sponsor 
or desi gnee to elucidate the nature and/or causalit y of the AE or SAE as fully as 
possible. This may include addit ional laboratory  tests or invest igations, 
histopathological examinat ions, or consultation with other healt h care professio nals.
If a participant dies during participation in the study or during a recognized fo llow-up 
period,the invest igator will provide the sponsor or desi gnee with a copy  of any 
post-mortem findi ngs including histopathology . 
10.3.5. Reporting of SAEs
SAE Reporting via Paper Form
Facsimile transmissio n of the SAE paper formis the preferred method to transmit this 
inform ation to the medical mo nitor or the SAE coordinator .
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE report within the designated reporting time f rames.
Contacts for SAE reporting can be found in the SAE report .
10.3.6. Regulatory Reporting Requirements
SAE Regulatory Reporting
Prom pt notificat ion by the invest igator to the sponsor of a nSAE is essent ial so that 
legal obligations and ethical responsibilit ies towards the safet y of parti cipants and 
the safet y of a study  intervent ion under clinical investigation are met.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
54●The sponsor has a legal responsibilit y to notify both the l ocal regul atory  
authori ty and other regul atory  agencies about the safet y of a study  intervent ion 
under clinical invest igation. The sponsor will co mply wit h country -specific 
regul atory  requi rements rel ating to safet y reporting to the regulatory  authori ty, 
IRB/IEC , and invest igators.
●An invest igator who receives an invest igator safety report describing a nSAE or 
other specific safet y informat ion (e.g., summary or list ing of SAEs) from the 
sponsor will review and then file it alo ng with the IBand will notify  the 
IRB/ IEC, if appropriate according to local requirements.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
5510.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Definitions
Woman of Childbearing Potential
A wo man is considered fertile fo llowing menarche and unt il beco ming postmenopausal unless 
perm anent ly steril e (see bel ow).
If fertilit y is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, addi tional eval uation shoul d be considered.
Women in the fo llowing categori es are not considered women of childbearing potential
1.Prem enarchal
2.Prem enopausal  female wi th 1 of the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
Docum ented bilatera l tubal  ligation
Bilateral tubal occlusio n 
For individuals wit h perm anent infert ility due to an alternate medical cause other than the 
above (e.g., Müllerian agenesis, androgen insensit ivity), invest igator discret ion shoul d be 
applied to determining stud y entry .
NOTE : Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female is defined as women wit h:
12 m onths of amenorrhea for women ≥55, wi th no n eed for follicle -stimulat ing hormone
12 m onths of amenorrhea for women >40 to ≤54years old with follicle -stimulat ing 
horm one≥40 m IU/mL and no other medical condition such as anorexia nervosa and not 
taking medicat ions during the amenorrhea (e.g. ,oral contraceptives, hormones, 
gonadotropin -releasing horm one, ant i-estrogens, sel ective estrogen- receptor modulators, 
or chemotherapy  that induced am enorrhea)
10.4.2. Contraception Guidance
Contraceptive use by men or women should be consistent with local regulat ions re garding the 
methods of contraception for those participat ing in clinical studies.
Male parti cipants:
are not required to adhere to con tracepti ve requi rements
Female participants:
Female participants of childbearing potential who are abst inent (if this is co mplete 
abstinence, as their preferred and usual lifest yle) or in a same -sex relati onship (as part of 
their pref erred and usual lifestyle) must agree to either remain abst inent or stay in a 
same -sex rel ationship wi thout sexual relat ionships with males. Periodic abstinence (e.g., 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
56calendar, ovul ation, symptothermal, post -ovulation methods), declarat ion of abst inence 
just for the duration of a study , and wi thdrawal  are not acceptabl e method s of 
contraception.
Female participants of childbearing potential, who are not abstinent as described above, 
must agree to use a highly effect ive method of contraception (that is, one with less than 
1% failure rate) such as combinat ion or oral  contraceptiv es, implanted/injected 
contraceptives, intrauterine devices, or sterile partner until 30 days after the last dose of 
study  medicat ion. 
o Female participants not of childbearing potential are not required to use 
contraception. This includes females who are:
Infert ile due to surgical sterilization (hysterectomy, bilateral 
oophorectomy , bilateral  salpingectomy , bilateral tubal occlusio n or tubal  
ligation) or congenital ano maly(for example, Mülleri an agenesis )
Postmenopausal , as defined above.
Collection of Pre gnancy Information
Male participants with partners who become pregnant
●The invest igator will attempt to collect pregnancy informat ion on any male 
participant’s female partner who beco mes pregnant while the male participant is 
in this study . This applies only  to m ale parti cipants who receive study  
intervent ion.
●After obtaining the necessary  signed informed consent from the pregnant female 
partner direct ly, the i nvest igator will record pregnancy informat ion on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the 
partner’s pregnancy. The female partner will also be fo llowed to determine the 
outcom e of the pregnancy . Informati on on th e status of the mother and child will 
be forwarded to the sponsor. Generally, the fo llow-up will be no longer than 6 to 
8weeks following the estimated delivery date. Any terminat ion of the pregnancy 
will be reported including fetal status (presence or abs ence of ano malies) and
indicat ion for the procedure. 
Female participants who become pregnant
●The invest igator will co llect pregnancy information on any female participant 
who beco mes pregnant while part icipating in this study . The init ial information 
will be recorded on the appropriate form and submitted to the sponsor within 
24hours of learning of a participant ’spregnancy . 
●The parti cipant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will co llect fo llow-up inform ationon the participant and the neonate, 
and the information will be forwarded to the sponsor. Generally, fo llow-up will 
not be required for longer than 6 to 8 weeks bey ond the estimated delivery  date. 
Any terminat ion of pregnancy  will be reported, including fetal status (presence or 
absence of ano malies) or indicat ion for the procedure.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
57●While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complicat ion or el ective terminat ion of a pregnancy  for medical  reasons will be 
reported as an AE o r SAE. 
●A spontaneous abortion (occurring at <2 0weeks gestational age) or still birth 
(occurring at > 20weeks gestational age) is always considered to be an SAE and 
will be reported as such. 
●Any poststudy  pregnancy -related SAE considered reasonably  related to the study  
intervention by the investigator will be reported to the sponsor as described in 
Secti on8.3.2 . While the invest igator is not obligated to actively seek this 
inform ation in former study  parti cipants, he or she may learn o f an SAE through 
spontaneou s reporting.
Any female part icipant who becomes pregnant while participat ing in the study  will discont inue 
study  interventi on. If  the participant is discont inued fro m the study  intervent ion, follow the 
standard discont inuat ion process and cont inue directly to the fo llow-up phase.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
5810.5. Appendix 5: Genetics
Use/Analysis of DNA
●Genet ic variat ion may impact a participant’s response to study  intervent ion, 
suscept ibilit y to, and severit y and progression o f disease. Variable response to 
study  interventi on may  be due to genetic determinants that impact drug 
absorpti on, di stribut ion, metabo lism, and excret ion; mechanism of act ion of the 
drug; di sease et iology; and/or mo lecular subt ype of the disease being treated. 
Therefore, where local regulat ions and IRB/IEC allow, a blood/saliva sample will 
be co llected for DNA analysis fro m consent ing parti cipants.
●DNA samples will be used for research related to selpercat inibor advanced or 
metastati c RET -mutant MTC/advanced or metastatic RET fusion -positive thy roid 
cancer/metastatic RET fusio n-positive NSCLC . They  may also be used to develop 
tests/assays including diagnost ic tests related to selpercatinib advanced or 
metastati c RET -mutant MTC/advanced or metastatic RET fusion -positive thy roid 
cancer/metastatic RET fusio n-positive NSCLC . Genet ic research may c onsist of 
the analysis o f one or m ore candidate genes or the analysis of genet ic markers 
throughout the geno me or analysis o f the ent ire geno me(as appropri ate).
●Addit ional analyses m ay be conducted if it is hypothesized that this may  help 
further unders tand the clinical data.
●The samples may  be analyzed as part of a mult i
-study  assessment of genetic 
factors i nvolved in the response to selpercat inibor study  interventi ons of  this 
class to understand study  disease or related condit ions.
●The results of genet ic analyses may be reported in the clinical study  report or in a 
separate study  summary.
● The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confident iality.
The samples will be retained while research on selpercatinib or study  
intervent ions of this class or indicat ioncontinues but no l onger than 15 y ears or 
other period as per local requirements .
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
5910.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments 
Hepatic Evaluation Testing –Refer to protocol Hepatic Safety Section 8.2.6.1 for guidance on 
appropriate test selection.
For testing selected, analysis is required to be comp leted by the Lilly -designated central 
laboratory except for Microbiology.
Local testing may be performed in addition to central testing when required for immediate 
participant management.
Results will be reported if a validated test or calculation is available.
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocytes (RBCs -Red Blood Cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -White Blood Cells) Alanine aminotransferase (ALT)
Differ ential: Aspartate aminotransferase (AST)
  Neutrophils, segmented Gamma -glutamyl transferase (GGT)
  Lymphocytes Creatine kinase (CK)
  Monocytes Other Chemistry
  Basophils Acetaminophen
  Eosinophils Acetaminophen Protein Adducts
Platelets Alkaline Phosphatase Isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
CoagulationCopper
Ethyl Alcohol (EtOH)
Prothrombin Time, Inter national Normalized 
Ratio (PT-INR)Haptoglobin
Serology Immunoglobulin IgA (Quantitative)
Hepatitis A Virus (HAV) Testing: Immunoglobulin IgG (Quantitative)
  HAV Total Antibody Immunoglobulin IgM (Quantitative)
  HAV IgM Antibody Phosphatidylethanol (PEth)
Hepatis B Virus (HBV) Testing : Urine Chemistry
  Hepatitis B surface antigen (HBsAg) Drug Screen
  Hepatitis B surface antibody (Anti -HBs) Ethyl glucuronide (EtG)
  Hepatitis B core total antibody (Anti -HBc) Other Serology
  Hepatitis B core IgM antibody Anti-nuclear antibody (ANA)
  Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA)a
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
60  HBV DNAdAnti-actin antibody b
Hepatis C Virus (HCV) Testing: Epstein -Barr Virus (EBV) Testing:
  HCV antibody   EBV antibody
  HCV RNAd  EBV DNAd
Hepatitis D Virus (HDV) Testing: Cytomegalovirus (CMV) Testing:
  HDV antibody   CMV antibody
Hepatitis E Virus (HEV) Testing:   CMV DNAd
  HEV IgG antibody Herpes Simplex Virus (HSV) Testing:
  HEV IgM antibody   HSV (Type 1 and 2) antibody
  HEV RNAd  HSV (Type 1 and 2) DNAd
Microbiologyc Liver Kidney Microsomal Type 1 (LKM -1) 
Antibody
Culture:
  Blood
  Urine
a This is not required if anti-actin antibody is tested.
b This is not required if ASMA is tested.
c Assayed by investigator -designated local laboratory ONLY; no Central Testing available.
d Reflex/confirmation dependent on regulatory requirements and/or testing availability.
Evaluation of participants with treatment -emergent abnormal hepatic biochemical tests 
during a clinical trial *
Test/Procedure: Rationale Action
Close Hepatic Monitoring
Clinical Chemistry:
  Total bilirubin
  Direct bilirubin
  Alkaline phosphatase (ALP)
  Alanine aminotransferase (ALT)
  Aspartate aminotransferase (AST)b
  Gamma -glutamyl transferase (GGT)
  Creatine kinase (CK)All: Routine follow -up
CK: Muscle injury/rhabdomyolysisUtilize a Hepatic 
Monitoring central lab 
collection kit and select 
Clinical Chemistry 
Hematology
  Hemoglobin
  Hematocrit
  Erythrocy tes (RBCs –Red Blood 
Cells)
  Leukocytes (WBCs –White Blood 
Cells)
  Differential:
  Neutrophils, segmentedInfection Utilize a Hepatic 
Monitoring central lab 
collection kit and select 
Hematology
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
61  Lymphocytes
  Monocytes
  Basophils
  Eosinophils
  Platelets
  Cell Morphology (RBCs and WBCs)
Medical history:a, h
  Symptoms
  Co-existing medical conditions
  Con comitant medications
  Dietary and nutritional supplements
  Exercise (excessive)
  Muscle Injury
  Alcohol consumption
  Illicit substancesUsed to evaluate/rule out:
  Systemic infection or sepsis
  Ischemic or congestive hepatic injury
  Gallstone disease
  Alcoholic liver disease
  Muscle injury/rhabdomyolysis
  Acetaminophen toxicity
  Drug-Induced Liver Injury ( DILI )due 
to another drug, herbal or dietary 
substancesIf findings are clinically 
significant, rep ort as an 
adverse event.
Hepatitis A Virus (HAV) Testing:
  HAV Total Antibody
  HAV IgM AntibodyUsed to evaluate/rule out: Acute HAV 
infectionUtilize a Hepatic 
Monitoring central lab 
collection kit and select 
Hepatitis A
Hepatis B Virus (HBV) Testing:
  Hepatitis B surface antigen (HBsAg)
  Hepatitis B surface antibody 
(Anti-HBs) 
  Hepatitis B core total antibody 
(Anti-HBc)
  Hepatitis B core IgM antibody
  Hepatitis B core IgG antibody 
  HBV DNAUsed to evaluate/rule out: Acute or 
exacerbation of chronic HBV infection. Utilize a Hepatic 
Monitoring central lab 
collection kit and select 
Hepatitis B
Hepatis C Virus (HCV) testing:c, d
  HCV antibody
  HCV RNAUsed to evaluate/rule out: Acute or 
exacerbation of chronic HCV infection. Utilize a Hepatic 
Monitoring central lab 
collection kit and select 
Hepatitis C
Hepatitis E Virus (HEV) Testing: e
  HEV IgG antibody
  HEV IgM antibody
  HEV RN AUsed to evaluate/ rule out: Acute HEV 
infection.Utilize a Hepatic 
Monitoring central lab 
collection kit and select 
Hepatitis E
Anti- nuclear antibody (ANA)
Anti-smooth muscle antibody (ASMA)
Anti- actin antibody
Immunoglobulin IgA
Immunoglobulin IgG
Immunoglobulin IgMUsed to evaluate/rule out: Autoimmune 
hepatitisUtilize a Hepatic 
Monitoring central lab 
collection kit and select 
only the specific test/s 
required. 
Hepatobiliary imaging:a, h
  Ultrasonography
  Computed tomography scan
  Magnetic resonance imaging
  Magnetic resonance 
cholangiopancreatography (MRC P)g
Endoscopic retrograde 
cholangiopancreatography (ERCP)gUsed to evaluate/rule out: 
  Biliary obstruction
  Pancreatitis
  Gallstones
  Portal -vein/ hepatic vein thrombosis 
  Hepatic metastasisPerformed locally.
If findings are clinically 
significant, report as an 
adverse event.
Comprehensive Hepatic Monitoring
Coagulation:
Prothrombin Time, INR (PT -INR)Used to evaluate/rule out:
Suspected liver failure, for patients with 
elevated Total BilirubinUtilize a Hepatic 
Monitoring central lab 
collection kit
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
62Epstein- Barr Virus (EBV) Testing:
  EBV antibody
  EBV DNA
Cytomegalovirus (CMV) Testing:
  CMV antibody
  CMV DNA
Herpes Simplex Virus (HSV) 
Testing:
  HSV (Type 1 and 2) antibody
  HSV (Type 1 and 2) DNAUsed to evaluate/rule out:
EBV or 
Hepatic injury due to CMV, or
HSV infection.Utilize a Hepatic 
Monitoring central lab 
collection kit and select 
only the specific test/s 
needed.
Liver biopsy fUsed to evaluate/rule out:
Autoimmune hepatitis (AIH)If findings are clinically 
significant, report as an 
adverse event.
Additional Hepatic Monitoring Tests
Alkaline Phosphatase Isoenzymes Used to evaluate/differentiate: Elevated 
Alkaline Phosphatase origination from
bone or liverUtilize a Hepatic 
Monitoring central lab 
collection kit
Liver Kidney Microsomal Type 1 
(LMK-1) AntibodyUsed to evaluate: Autoimmune hepatitis Utilize a Hepatic 
Monitoring central lab 
collection kit
Urine Chemistry:
  Ethyl glucuronide (EtG) i
Other Chemistry:
  Phosphatidylethanol (PEth)jUsed to evaluate: Alcoholic liver 
disease Utilize a Hepatic 
Monitoring central lab 
collection kit
Other Chemistry:
  Acetaminophen
  Acetaminophen Protein AdductsUsed to evaluate: Acetaminophen 
toxicity Utilize a Hepatic 
Monitoring central lab 
collection kit
Ethyl Alcohol (EtOH) Used to evaluate recent alcohol 
consumptionUtilize a Hepatic 
Monitoring central lab 
collection kit
Haptoglobin Used to evaluate a diagnosis of 
hemoly sisUtilize a Hepatic 
Monitoring central lab 
collection kit
Cardiology consulta
Electrocardiogram
Echocardiogram
Vital Signs:
  Blood pressure
  PulseUsed to evaluate: Ischemic or 
congestive hepatic injuryPerformed locally.
If findings are clinically 
significant, report as an 
adverse event.
Urine Chemistry:
  Drug screenUsed to evaluate: Hepatotoxicity due to 
cocaine, opiates and other illicit 
substances Utilize a Hepatic 
Monitoring central lab 
collection kit
Hepatitis D Virus (HDV) Testing:
  HDV antibodyUsed to evaluate/rule out: Acute HDV 
infection.Utilize a Hepatic 
Monitoring central lab 
collection kit and only 
select required test needed.
Microbiology: 
Cultures:
  Blood
  UrineUsed to evaluate/rule out: 
Sepsis or systemic infectionPerform locally.
If findings are clinically 
significant, report as an 
adverse event.
Slit-lamp eye examination 
(Kay ser-Fleisher rings)
Genetic evaluationUsed to evaluate/rule out: 
Wilson’s disease Perform locally. 
If findings are clinically 
significant, report as an 
adverse event.
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
63Other Chemistry:
  Ceruloplasmin
  CopperUsed to evaluate/rule out: 
Wilson’s disease Utilize a Hepatic 
Monitoring central lab 
collection kit
*This tool is to be used by the investigative site for reference during the evaluation of a participant who met hepatic 
monitoring criteria based on laboratory results and clinical judgment for a suspected liver injury during protocol 
participation. 
aExtent and type of work -up may  vary  by participant’s history, severity of liver injury, underlying disea se, and 
geography.
bSerum AST typically (although not always) is higher than ALT .
cIf anti -HCV is positive, HCV RNA is required to confirm HCV infection .
dAcute hepatitis C may be anti -HCV negative but HCV RNA positive .
eIf anti -HEV IgM is positive, consider confirmation with HEV RNA by nested polymerase chain reaction.
fA liver biopsy is needed to confirm a diagnosis of AIH .
gIf cholestatic injury , MRCP or ERCP may be recommended .
hBased on medical history and clinical judgment .
iAlcohol consumption in past 3 to 5 days .
jAlcohol consumption in past 3 weeks .
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
6410.7. Appendix 7: Abbreviations and Definitions
Term Definition
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
CFR Code of Federal Regulations
CI confidence interval
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a d rug o r drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CP clinical pharmacologist
CRP clinical research physician: Individual responsible for the medical conduct of t he study . 
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
GCP good clinical practice
IB investigator’s brochure
IEC independent ethics committee
ICF informed consent form
ICH Inter national Council for Harmonisation
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
65informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Informed consent is 
documented by means of a written, signed and dated informed consent form .
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further inform ation about the authorized form.
IRB institutional review board
NSCLC Non-small cell lung carcinoma
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal p roduct or as a control
PC product complaint
PFOS powder for oral suspension
PK pharmacokinetics
QTc corrected QT interval
QTcB corrected QT interval using Bazett’s formula
QTcF corrected QT interval using Fridercia’s formula
QTL quality  tolerance limit
RTU ready touse
SAE serious adverse event
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SoA schedule of assessments
TBL total bilirubin
ULN upper limit of normal
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
6610.8. Appendix 8: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.
Amendment [ a]: (07-Sep-2021)
This amendment i s consi dered to be nonsubstant ial.
Overall Rationale for the Amendment:
The protocol is amended to correct the timepo ints for clinical laboratory  assessments in the 
Schedule of Act ivities.Minor edi torial changes have been done which is not reflected in the 
below table. The fo llowing table describes the change made in amendment ( b).
Section # and Name Description of Change Brief Rationale
1.3 Schedule of 
Activities (SoA)Added t imepo ints for collect ion 
of PK samples in the table and 
deleted the following 
inform ation in the footnotes 
“Samples will be taken at the 
following t imepo ints on Days 
1,8 and 15: predose, and 0.5, 
0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 
12, 24, 36, 48, 72, 96, 120, 144 
hours postdose” from footnote of 
Schedule of Act ivities (SoA) 
table for consi stent presentation.
Added PK sample -Selpercatinib 
(plasma) timepo int for early 
discontinuat ion (ED).To rem ove the addi tional 
PK sampling timepo ints 
that were inadvertent ly 
added in Original Protocol. 
1.3 Schedule of 
Activities(SoA)Added Single 12 -lead ECG 
assessment at ED.Missing 12 -lead ECG 
assessment added.
1.3 Schedule of 
Activities (SoA)A co mment has been added to the 
Taste Assessment Questionnaire 
“To be perform ed for the RTU 
suspension and PFOS 
formulations only  immediately 
after dosing”.To cl arify taste assessment 
will be measured after 
dosing . 
1.3 Schedule of 
Activities (SoA)Deleted the foot note “Vital signs 
assessments on Day s 5and14 
shoul d be perfo rmed in the 
morning at a time relat ive to To correct the schedule of 
activit ies for the missing 
vital signs measurement 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
67Section # and Name Description of Change Brief Rationale
predose on Day s 1 and 8,
respectively ”.
Added “ Assessments on Day s 5 
12, and 19 should be performed 
in the morning at a time relat ive 
to predose on Days 1, 8 and 15, 
respectively” to the table.
Timepo ints for vital signs 
measurement 
added on Day  9, 12, 16 and 1 9
deleted on Day  14.timepo ints in the original 
protocol .
10.2.1 Bl ood 
Sampling SummaryAdded Blood sampling Summary  
table.This summary  table was 
missed in Original Protocol .
10.4.2 Contraception 
GuidanceAdded Bilateral tubal occlusion .This procedure was 
inadvertent ly missed in 
Original  Protocol . 
CONFIDENTIAL Protocol  number J2G-MC-JZJU (b) 
6811. References
Levey  AS, Stevens LA, Schmid CH, et al. A New Equati on to Estimate Glo merular Filtrat ion 
Rate. Ann Interim Med. 2009;150(9):604 -612.
LOXO -RET -19075 Clinical Study Report: An Open -Label , 3-Period, Fixed Sequence Study  to 
Evaluate the Effect of an H 2 Antagoni st and a Proton Pump Inhibitor on the Single Dose 
Pharmacokinet ics of LOXO -292 in Healt hy Adult Subjects
Leo Document ID= 226ad363-bc7a-4644-857d-2bbfb8e89309 
Approver: PD --------------
Approval Date & Time: 22-Nov -2021 13:37:44 GMT 
Signature meaning: Approved 
Approver: PPD ----------------
Approval Date & Time: 22-Nov -2021 19:01:20 GMT 
Signature meaning: Approved 